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ABSTRACT
Complex regional pain syndrome type-I (CRPS-I) is a debilitating pain disorder often
occurring secondary to distal extremity trauma. Its pathophysiology is not well
understood; however, microvascular dysfunction is proposed as an important factor
in its development and maintenance. Using a rodent model, we tested an automated
gait analysis system (CatWalk™) to examine functional changes. In addition, the use
of carbon monoxide releasing molecule-3 (CORM-3), a compound known to be a
potent vasodilator and anti-inflammatory agent, was also tested as a treatment of
CRPS-I-like symptoms. Using the CatWalk™ system, we observed significant
changes in gait parameters post-injury, several of which persisted throughout the 14day experiment. CORM-3 administration significantly reduced mechanical allodynia
symptoms, as demonstrated through the restoration of withdrawal thresholds during
mechanical stimulation testing. Functional deficits were not restored after CORM-3
application; however, trends for improvement were observed. CORM-3 has
relevance as a potential therapy to alleviate symptoms associated with CRPS-I.

Keywords: complex regional pain syndrome type-I, CORM-3, microcirculation, gait
analysis, CatWalk™, carbon monoxide, chronic pain
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CHAPTER 1
INTRODUCTION AND HISTORICAL REVIEW
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CHAPTER 1:

INTRODUCTION AND HISTORICAL REVIEW

1.1 COMPLEX REGIONAL PAIN SYNDROME
In the clinic, persistent and chronic pain is the most common reason for
patient presentation (Von Korff et al., 1988; Von Korff et al., 2008). Our current
understanding of pain sensation and pain mechanisms in both normal and
pathological conditions is continuously expanding and helping physicians to better
cope with the increasing load of chronic pain patients. Headway has been made to
recognize pain as a disease in its own right, as several studies show that over 1 in 5
Canadians are affected by chronic pain. According to the Chronic Pain Association
of Canada, “The cost of chronic pain for Canadians is well over 40 billion dollars in
direct and indirect costs. This is more than cancer, HIV, and heart disease
combined.” (Lynch, 2011) One such chronic pain condition, Complex Regional Pain
Syndrome, has both significant direct and indirect costs on our society, and its
peoples.
Complex Regional Pain Syndrome (CRPS) describes a range of painful
conditions and is characterized by a continuing regional pain – either spontaneous
or induced – that is disproportionate to the inciting event or the usual course of a
known trauma, in both time and degree. It typically occurs secondary to an extremity
trauma and has a distal presence of abnormal sudomotor, vasomotor, sensory,
motor and/or trophic signs (Bean et al., 2014; Bruehl et al., 2002; Harden, Bruehl,
Perez, Birklein, Marinus, Maihofner, Lubenow, Buvanendran, Mackey, Graciosa,
Mogilevski, Ramsden, Schlereth, et al., 2010). Typical symptoms include a constant
burning pain, mechanical and cold allodynia, swelling, temperature changes and
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limited active range of motion of the limb; exacerbation of symptoms is often
observed upon exertion and exercise as well (M. Stanton-Hicks et al., 1998). Other
considerable symptoms include severe motor dysfunction (dystonia, tremors,
weakness, incoordination), dystrophy, psychiatric co-morbidities, sweating, bone
changes, and changes in hair and nails. Anxiety and depression are common to this
disorder, as patients often do not respond to any available treatment. Current
therapeutic options include pharmacological, surgical, psychological and physical
therapy (Harden, 2000; M. D. Stanton-Hicks et al., 2002). As a result of often failing
treatment attempts, there is a push towards translational research in the study of
CRPS. Although the triggers of the disorder are known (soft tissue injuries, fractures,
sprains, crush injuries, surgery, spinal cord disorders and infections), CRPS
sometimes occurs spontaneously, making it extremely difficult to diagnose (Wasner
et al., 2001; Wilson et al., 2005). Diagnostic criteria are constantly evolving, as the
consequences of a misdiagnosis can have multiple implications in patient quality-oflife, employment status, and healthcare costs. As suggested by Harold Merskey’s
quote below, pain is devastating to a person’s livelihood:
“If I have matters right, the consequences of pain will include direct physical
distress, unemployment, financial difficulties, marital disharmony, and
difficulties in concentration and attention…” (Merskey, 2000).
In order to help better understand the complex mechanisms underlying the
pathophysiology of CRPS, and to develop accurate assessments for patients, both
basic science and clinical research modalities are jointly needed.
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1.2 HISTORY OF CRPS
The history of CRPS traces back to 16th century European battles, where
severe pain symptomology from trauma, induced by lance (and later, bullet) injuries,
was reported (Bonica, 1953). Potts, a famous British surgeon, reported in the 18th
century that trauma of the extremities can result in pain and atrophy (Hooshmand,
1993). One of the first amputations was actually performed by a surgeon named
Denmark on sailors whose musket bullet injuries resulted in severe burning pain with
inflammatory symptoms; this condition was termed “tic douloureux” at the time (Ley,
1835). Throughout the next several hundred years, the nomenclature and definition
of the disorder has seen many changes; however, no concrete description of the
pathophysiology has been accepted.
In the 19th century and the American Civil War, a physician named Wier
Mitchell is accredited with describing the burning pain soldiers suffered from gunshot
wounds and attributing it to a specific condition. He called the condition ‘causalgia’, a
name originating from the greek word kausos for fever (from kaiein for “to burn”)
(Mitchell, 1867). Together, Mitchell and William Keen (another doctor serving the
Turner Lane Hospital in the Civil War) studied several nerve injuries, and eventually
published “Gunshot Wounds and Other Injuries of the Nerves and Reflex Paralysis”,
which described causalgia and secondary paralysis (Mitchell, 1864). In their
publications, Mitchell, Keen and others described the severe burning pain, abnormal
skin colour and temperature, sweating, muscle weakness, osteoporosis and
involuntary movements that many soldiers experienced; effectively, well describing
the disease (Mitchell, 1864, 1867). It wasn’t until 1916 that a proposal for the
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mechanisms of causalgia was suggested by Leriche, who proposed that the
sympathetic nervous system had an important role (Leriche, 1916).
Suggesting a much different view on the source of pain, Paul Sudeck, a
German physician, theorized that the bone atrophy and other symptoms observed
were part of an inflammatory reaction after trauma. The syndrome was then referred
to as Sudeck’s atrophy (Sudeck, 1902; van der Laan et al., 1998; Veldman et al.,
1993).
William Livingston, an American surgeon during the Second World War,
described a “vicious cycle” used to explain CRPS symptoms. The cycle explains
how afferent input and reflex vasoconstriction could trigger pain, limb disuse and
atrophy with even the most minor of nerve injuries (Livingston, 1948). From his
hypothesis, Livingston performed many sympathectomies on suffering soldiers,
some of which experiencing transient relief of pain symptoms. The findings resulted
in Livingston suggesting an important role of the sympathetic nervous system in
causalgia (Livingston, 1948).
Around the same time Livingston was performing sympathectomies on injured
soldiers, a surgeon by the name of Philip Foisie was hypothesizing the roles of
arterial vasospasm and ischemia, from arterial and soft tissue injury, in causalgia
(Foisie, 1947). Until then, vasospasms and ischemia had been largely ignored as
potential factors contributing to CRPS.
Formally called minor causalgia, the term “Reflex Sympathetic Dystrophy”
(RSD) was introduced by John Evans in 1946, and referred to as causalgia without a
visible major nerve injury (Evans, 1946, 1947). In 1986, the International Association
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for the Study of Pain (IASP) defined RSD as “continuous pain in a portion of an
extremity after trauma, which may include fracture but does not involve a major
nerve, associated with sympathetic hyperactivity.” An additional definition, proposed
by an Ad Hoc committee of the American Association of Hand Surgery, called RSD
“a pain syndrome in which the pain is accompanied by loss of function and evidence
of autonomic dysfunction.” However, in order to avoid any mechanistic term in its
appellation, RSD had been renamed, as many cases did not seem to have
sympathetically maintained pain, nor did result in dystrophy. Together, causalgia and
RSD have had many different names describing them (Table 1.1).
A discussion at the IASP Task Force on Taxonomy in 1994 resulted in a new
umbrella term: Complex Regional Pain Syndrome (CRPS), which is now used
instead, as there is “neither clinical nor pathological evidence to suggest that the
mechanisms are any different in these two syndromes, and the responses (or lack
thereof) to treatments are quite similar” (Wilson et al., 2005). Two types of CRPS are
defined: CRPS-I, which encompasses what was formally RSD, and CRPS-II, which
is what was formally known as causalgia. Type-I differs from type-II solely on the
absence of a distinct nerve injury (Harden et al., 2007).
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Synonyms of Complex Regional Pain Syndrome

Synonyms of Complex Regional Pain Syndrome
Reflex sympathetic dystrophy (RSD)
Causalgia
Sudeck’s atrophy
Post-traumatic dystrophy
Shoulder-hand syndrome
Algodystrophy
Algoneurodystrophy
Reflex neurovascular disease
Pourfour du Petit syndrome
Postinfractional sclerodactylia
Fracture disease
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1.3 DIAGNOSIS OF CRPS
Sensitivity and accuracy of CRPS diagnosis is imperative to our health care
system and patient quality of life. Being diagnosed with CRPS has serious
implications to a patient’s ability to work and to maintain the livelihood of their
families. A study by Kemler and Furnee (2002) concluded that the impact of chronic
pain on both patients and their families could be unbearable physically and
financially (Kemler & Furnee, 2002). They found that CRPS had a profound effect on
employment status, time allocation, additional domestic help and out-of-pocket
expenses (Kemler & Furnee, 2002). Therefore, early and accurate diagnosis and
prompt management of symptoms are essential in reducing or preventing CRPS
from worsening, as well as improving quality of life.
In Budapest, IASP consensus updated the diagnostic criteria for CRPS.
Harden et al (2007) summarized the group’s revisions to the former diagnostic
criteria, which aimed to reduce both over- and under-diagnosis of CRPS while
maintaining diagnostic sensitivity (Harden et al., 2007). To make a CRPS diagnosis,
the new criteria states that a patient must have:
1. Presence of an initiating noxious event, or a cause of immobilization;
2. Continuous pain, allodynia and/or hyperalgesia in which the pain is
disproportionate to the inciting event;
3. Evidence at some time of edema, changes in skin blood flow or abnormal
sudomotor activity in the region of pain;
4. This diagnosis is excluded by the existence of other conditions that would
otherwise account for the degree of pain and dysfunction.
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The diagnosis is further clarified if the patient is seen with or without major nerve
damage. Nerve damage would result in a diagnosis of CRPS-II, whereas no nerve
damage would garner a diagnosis of CRPS-I. The presence of an initiating noxious
event may be unrequired as 5-10% of CRPS patients develop the syndrome
spontaneously (Harden et al., 2007).
Considering that CRPS symptoms often vary slightly between patients and
over time, probably as a result of a different contribution to symptoms from different
pathophysiologic mechanisms, a clinical diagnosis has to meet several criteria.
Clinicians examine four categories of symptoms: sensory (hyperesthesia and
allodynia), vasomotor (temperature and skin colour changes), sudomotor/edema
(edema and sweating changes and asymmetry), and motor/trophic (decreased
range of motion; motor dysfunction like weakness, tremor and dystonia; trophic
changes like hair, nail, and skin) (Harden et al., 2007). To make a clinical diagnosis
of CRPS, the following criteria must be met:
1. Continuing pain disproportionate to the inciting event;
2. Patient reporting at least one symptom in at least three of the four categories
listed above (sensory, vasomotor, sudomotor/edema and motor/trophic);
3. Patient must display at least one sign in two or more of the above categories
at the time of evaluation;
4. No other diagnosis better explains the signs and symptoms.

Clinically, the above criteria were agreed upon because, compared to the previous
IASP diagnostic criteria, they limit false positives. However, depending on the
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purpose for which the criteria are intended, the sensitivity and specificity of criteria
might need adjusting. For example, in the research context, identifying stringent
research samples by minimizing false positives is valuable, compared to clinically
identifying as many CRPS cases as possible by minimizing false negatives (Harden
et al., 2007). For this reason, diagnostic criteria in research are adjusted. In
research, two of four sign categories and four of four symptoms categories must be
positive for a CRPS diagnosis (Harden et al., 2007). These result in the greatest
probability of CRPS vs non-CRPS according statistical analyses performed by
Harden et al (2007).

1.4 THERAPEUTIC APPROACHES AND MANAGEMENT
Over the last few decades, treatment plans for CRPS have adapted to new
knowledge; however, the lack of consensus in the pathophysiology of the disorder
have proved to make developing appropriate therapies very difficult, to say the least.
Early recognition and treatment of CRPS-I are important because CRPS-I patients
are at high risk of developing severe disability in the affected limb, potentially
compromising future employment and livelihood (Poplawski et al., 1983).
Norman Harden presented a very good summary of why treatment of CRPS
is inherently so difficult. It stated:

“The syndrome is inherently complex biomedically, involving both peripheral
and central pathophysiology, but it also often has psychosocial features that
are critical diagnostic elements (and treatment targets). Successful treatment
is further complicated by the diversity of patient presentation and by
antecedent pathology. In addition to these clinical challenges, the
epidemiology and natural history of CRPS are poorly understood. Even
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research data are challenging to interpret, and evidence has been slow to
accumulate as to how best to treat CRPS, due in large part to the vagaries of
diagnosis (see Chapter 4). How is a specialist to begin treating such a
multifaceted condition?” (Wilson et al., 2005)

Indeed, how is a specialist to begin treating such a multifaceted condition?
This question was address by Harden and others in CRPS: Current Diagnosis and
Therapy in 2005, after an IASP conference in Budapest. The authors also presented
a general treatment algorithm, suggesting an interdisciplinary method for handling
CRPS, with a focus on functional restoration. This algorithm recommends the use of
conservative care, via physical/occupational therapy and oral medications, when a
patient continues to have persistent pain or dysfunction. With regular consultation, if
a patient continues to experience CRPS symptoms with conservative care,
intermittent regional nerve blocks are then sometimes prescribed. If a failure to
progress from nerve blocks were observed, a move to infusion techniques (i.e
epidural infusions) would be recommended. If CRPS symptoms persist, the patient
may be a candidate for spinal cord stimulator implantation or intrathecal drug
delivery. These options are more invasive and should only be considered if other
therapies fail; additionally, the authors suggest intrathecal drug delivery should only
be considered if spinal cord stimulation fails to relieve symptoms, or if a patient
exhibits a plateau of response (Wilson et al., 2005). Such treatments will be
discussed further in the following sections. Of course, CRPS is a very complex
condition and treatments cannot be expected to be identical between patients. The
basic principle of the functional restoration guidelines is to identify progress through
the steps of care, and to intervene with additional treatments if patients do not
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progress (Wilson et al., 2005). Treatment guidelines emphasize using a multidisciplinary approach, to compassionately and methodically help patients regain
their quality of life.
The development of additional treatments, targeting potential mechanisms
explaining the initiation and maintenance of CRPS, are needed. Patients are often
frustrated by the lack of relief pain management regimens provide; the development
of adjunct therapies may help both clinic and patient relieve pain and frustration.

1.4.1 Rehabilitation Therapy
In keeping with the focus on functional restoration, rehabilitation therapy is an
important part in CRPS treatment. Until recently, rehabilitation has been stated as
vital, or at least a supportive complementary approach to CRPS; however, its
techniques, frequency and intensity are rarely described in the literature. Instead,
writings tend to focus on explanatory hypotheses, medical interventions and
adjustments to diagnostic criteria.
Rehabilitation is the culmination of both physical and occupational therapy,
with the aim of focusing treatments on the clinical manifestations of CRPS, including
edema, restricted range of motion, temperature sensitivity, intolerance of physical
activity, reduced muscle strength and, of course, pain. Although physical and
occupational therapists differ in their scope of practice, much of their work overlaps
in the treatment of a chronic pain syndrome (Wilson et al., 2005).
In the treatment of CRPS, the first steps are often to manage edema and
pain. The next goal is the initiation of gentle, active movements, to restore range of
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motion. Finally, improvement of muscle strength and function of the extremity are
targeted to fulfill the end goal of improving whole body function, to allow patients to
be participating members of society (Bengtson, 1997). In a prospective randomized
control trial that followed patients over the course of 1 year, physical and
occupational therapy modalities led to recovery from CRPS of the upper extremity
(Oerlemans et al., 1999).
Reducing edema is often achieved through lymph draining and by active
exercises; however, a study by Uher et al (2000) observed no difference between
active exercises and active exercises plus lymph draining. This would suggest that
physical therapy may be more effective in reducing edema (Uher et al., 2000).
Providing a balanced and varied approach to managing symptoms, physical
and occupational therapy as part of the rehabilitation method is currently the pivotal
intervention for CRPS, as determined by several large consensus meetings (Harden,
Bruehl, Perez, Birklein, Marinus, Maihofner, Lubenow, Buvanendran, Mackey,
Graciosa, Mogilevski, Ramsden, Chont, et al., 2010; Harden et al., 2007). As
confirmed in rat models, normalization of function may serve to reverse changes
observed in CRPS patients (Guo et al., 2004).
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1.4.2 Medications and Pharmacotherapy
As a result of a lack of efficacy of rehabilitation therapy for CRPS patients,
pharmacotherapy often becomes the major treatment option for those patients
whose symptoms do not improve. Of course, used in conjunction with other
therapies as directed by pain specialists, medications are prescribed for both early
and chronic CRPS, as well as chronic CRPS symptoms other than pain.
Since CRPS is often initiated by trauma or injury, most studies examining
treatments and therapeutic approaches have been performed by surgeons,
orthopaedists or rehabilitation specialists. As stated previously, acute CRPS is
characterized by pain and inflammation; however, it’s believed that the final effects
on the central nervous system may not have occurred yet, leaving an important
window for treatments to potentially affect the disease course (Wilson et al., 2005).
The mechanisms and targets of treatment are probably different in acute and chronic
CRPS, and there are very few studies investigating the effectiveness of early CRPS
treatments on chronic CRPS patient symptoms.
Some evidence-base studies have found that treatments prescribed in early
CRPS

include:

corticosteroids,

calcium-regulating

drugs,

alpha-adrenergic

antagonists, and anti-oxidants. A study by Christensen et al (1982) found that
systemic corticosteroid (prednisone) treatment reduced entire clinical status by more
than 75%; however, corticosteroids are typically not administered in chronic CPRS
patients (>6 months) as it has little efficacy (Christensen et al., 1982). Prednisone
and methylprednisolone are agents with anti-inflammatory properties, probably
affecting neurogenic inflammation and subsequently pain symptoms.
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Calcium-regulating drugs like clodronate and alendronate, as well as the

hormone calcitonin, have been found to improve swelling, pain, and range of motion
in several randomised clinical trials (RCTs) (Braga, 1994; Manicourt et al., 2004;
Perez et al., 2001; Varenna et al., 2000; Zyluk, 1998). The mode of action of these
treatments is not clear.
Considering the hypothesis that CRPS is caused by oxygen-derived free
radical damage that potentiates inflammation and microvascular dysfunction, several
studies have investigated antioxidants and free-radical scavengers as possible
therapeutics. One such study found that topical dimethylsulfoxide (DMSO) provided
alleviating effects (Zuurmond & Perez, 2006); however, a strong garlic odour in
exhaled breath was observed as an adverse effect.
Alpha-adrenergic antagonists and vasodilators have also been examined in
CRPS patients; although two studies show potential benefits of the alpha-adrenergic
antagonist phenoxybenzamine in both early and chronic CRPS (Ghostine et al.,
1984; Muizelaar et al., 1997), adverse effects of hypotension from vasodilatory
action are very serious.
In Table 1.2 below, the major classes of medications, with documented
efficacy, used in the treatment of chronic pain are summarised. Bearing in mind the
wide range in CPRS symptom presentation, no single medication is better or worse
than others, so clinicians must consider patient symptoms, age, circumstances and
personal history when prescribing medications.
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Table 1.2.

Major Classes of Medications Used in Treating Chronic Neuropathic
Pain

Treatment
Topical local anesthetics

Medication Name
•

Local anesthetic cream, gel, ointment

•

•

Tricyclics

Antiepileptics

Lidocaine 5% patch

•

Desipramine

•

Gabapentin

Carbamazepine (extended release)

•

•
•

Opiods

•

Tramadol

Oxycodone (extended release)
Morphine (extended release)
•

Adapted from Wilson et al 2005 (Wilson et al., 2005)

	
  

Nortiptyline

Methadone
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With minimal complications to its use, local anesthetics have active

ingredients that act locally at the site of application, typically the affected extremity
(Wilson et al., 2005). These agents differ from other transdermal medications like
fentanyl, which have a systemic distribution once absorbed across the skin. Gels,
creams, sprays and patches with active anesthetic ingredients (like lidocaine) are
supported by level 2 evidence for relief of allodynia symptoms in CRPS. The 5%
lidocaine patch is especially popular since it both covers the skin from potential
contact and has active anesthetic to relieve allodynia symptoms (Wilson et al.,
2005).
Tricyclics, or tricyclic antidepressents (TCAs), are perhaps the most beneficial
pharmacological CRPS therapy in use today (Jensen, 2002). Several trials have
found TCAs to be effective in reducing neuropathic pain (Jensen, 2002; Max et al.,
1987; Max et al., 1992; Raja et al., 1992; C. P. Watson et al., 1992). They also
happen to be one of the most inexpensive therapeutic options, as generic forms of
the agent are available. To decrease CRPS symptoms, TCA acts on several
mechanisms to alter noradrenergic inhibitory pathways for decreased dorsal horn
hyperactivity as well as the depression and psychological changes that accompany
the disorder. Use in the elderly is discouraged, however, since some TCAs (such as
amitriptyline) may contribute to cardiac arrhythmias.
Currently FDA-approved for use in epilepsy and post-herpetic neuralgia
(PHN), some antiepileptic drugs also exhibit antihyperalgesic properties, by
decreasing central neuronal hyperexcitability (Wilson et al., 2005). Gabapentin, the
best-studied antiepileptic, has been deemed efficacious and safe for CRPS patients
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after a study giving patients 600 mg/day (Mellick & Mellick, 1997). Its action is
thought to be the binding of alpha-2-delta subunit of voltage-gated calcium channels
for the decrease of synthesis and release of excitatory neurotransmitters (Gee et al.,
1996). Compared with TCAs, gabapentin has no drug-drug interactions and no
serious adverse effects; however, other anticonvulsants and antiepileptics have
inconclusive evidence as to their efficacy in pain disorders like CRPS.
The last major class of medication used in the treatment of CRPS patients is
the opioid medications. Reluctance to prescribe opioids is common amongst
practitioners for several reasons, including a potential for severe substance abuse
and addiction, evidence for the cause of diffuse pathological hyperalgesia after longterm opioid use, and physical tolerance at certain doses (applicable to other
medications as well) (Wilson et al., 2005). Although there are several consequences
of opioid use to consider before prescribing, there is abundant level 2 support for the
use of opioids in other painful conditions, including PHN and painful diabetic
neuropathy (PDN). Similar to TCAs, opioids do not cause any cognitive deficits as
detected by neuropsychological testing (Wilson et al., 2005). One study by Watson
and Babul (1998) found that controlled-release oxycodone at 60 mg/day contributed
to a 35% reduction in pain in PHN (C. P. Watson & Babul, 1998); other studies show
oxycodone ability to reduce pain by 30% in PDN as well (Gimbel et al., 2003; C. P.
Watson & Babul, 1998; C. P. Watson et al., 2003). Tramadol is an opioid suggested
to have similar effects in both PDN and other painful neuropathies (Sindrup et al.,
1999). The data for use in CRPS is inadequate as there are limited RCTs with solid
conclusions; however, opioid treatment is currently prescribed.
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Thus, pharmacotherapy can reduce symptoms of CRPS; however, there are

several drawbacks to the indefinite use of medications: in most patients, only a
temporary or partial relief from symptoms is provided, unable to “cure” CRPS. Other
treatments (e.g. electrical stimulation) have been found to have disease-modifying
effects, such as persistent pain relief even after treatment is complete (Wilson et al.,
2005). Another limitation is the length of therapy; the median age of CRPS is
approximately 40 years (Wilson et al., 2005), thus these patients may potentially
need to take prescription medications for decades. Not only are the long-term effects
of prolonged medication use generally unknown, but the long-term use may have
significant impacts on social, economic, and medical aspects of patient livelihood.
Currently, much of the evidence-based pharmacotherapy comes from data
extrapolated from RCTs for other diseases. Therefore, further work investigating
potential disease-modifying or protective agents, as well as performing RCTs
specific to CRPS patients, is needed.

1.4.3 Injection Therapy	
  
Traditional interventional therapies also include symptom relief though
injection of various compounds. CRPS was formally named reflex sympathetic
dystrophy for the implied mechanistic involvement of the sympathetic nervous
system; this belief led to various treatments aimed at sympathetic blockade.
Although

there

is

indeed

sympathetic

nervous

system

involvement

(i.e

sympathetically-maintained pain (SMP)), CRPS is a complex disease where
sympathetic blockade does not always provide relief. Sympathetic nerve block does,
however, provide insight into the diagnosis of pain in CRPS patients as either SIP or
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SMP. Common blocks include: sympathetic nerve blocks, intravenous regional
anesthesia (IVRA), intravenous infusions and others.
Depending on the location of symptoms, sympathetic nerve blocks are
traditionally delivered at the level of stellate ganglion or lumbar sympathetic chain
(Wilson et al., 2005). Sometimes, pain relief is evident even after the effects of local
anesthesia have expired; in some cases, pain relief may be long-lasting (Burton &
Waddell, 1998; Price et al., 1998). In 2002, a systematic review by Cepeda and
colleagues of over 79 reports on sympathetic blockade found that most reports had
to be rejected as CRPS diagnostic criteria has evolved markedly in the last 100
years (Cepeda et al., 2002). After pooling the data from only 29 remaining studies,
Cepeda and colleagues found that only 17% of 454 patients had partial or complete
pain relief; the duration of pain relief varied significantly and Cepeda also concluded
that it may be inaccurate to pool much of this data together. Overall, there is some
evidence for the benefit of classic sympathetic nerve blocks; however, they still
remain in most treatment plans as either a test to differentiate SMP from SIP, or to
help supplement active rehabilitation/physical therapy regimens.
IVRA is a fairly simple technique used to relieve pain symptoms by delivering
anesthetic directly to the affected limb. This is performed by injecting an anesthetic
compound, or a mixture of several compounds, into the circulation of the affected
limb, while isolating the limb from the rest of circulation with a tight-fitted tourniquet
(Davis et al., 2002). The likely mechanism for the block of sympathetic nerves is
through vascular beds around peripheral nerves, the vasa nervorum and valveless
venules around nerve endings (Wilson et al., 2005); diffusion of the local anesthetic
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into local tissues may also be involved. Several high-quality studies have been
published comparing local anesthetics delivered by IVRA including guanethidine,
lidocaine, bretylium, clonidine, droperidol, ketanserin and reserpine (Forouzanfar et
al., 2002; Kingery, 1997; Perez et al., 2001).
Intravenous infusions of phentolamine and lidocaine have also been studied
for the relief of pain symptoms. Intravenous infusion involves the controlled injection
of fluid into the circulatory system by an infusion pump. Studies differ on the effect of
phentolamine; a study by Arner et al (1991) reported an analgesic effect in both
adults and children with CRSP-I and II, but Verdugo and Ochoa (1994) found that
neither placebo nor phentolamine provided any changes in pain, blood flow or
sensory testing after a prospective, single-blinded study (Arner, 1991; Verdugo &
Ochoa, 1994). Intravenous infusions are not used as much recently and when used,
they often act as a diagnostic tool to differentiate SIP and SMP.

1.4.4 Psychological Interventions
Similar to several other chronic pain disorders, CRPS is a complicated
biopsychosocial disorder that requires multidisciplinary treatment in order to improve
psychological, social and medical aspects of patient health. Currently, there are very
limited controlled studies examining the efficacy of different types of psychological
intervention; however, there are several approaches that have shown benefit. These
include relaxation training, biofeedback, cognitive intervention and hypnotic imagery
(Wilson et al., 2005). As part of a multidisciplinary treatment package, many of the
above approaches have yielded significant alleviation of CRPS symptoms. A RCT by
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Oerlemans et al (1999 and 2000) of 135 adult CRPS patients concluded that
relaxation training and cognitive interventions in conjunction with physical therapy
yields a significantly greater improvement in CRPS symptoms than controls at a
one-year follow up (Oerlemans et al., 1999; Oerlemans et al., 2000). Several case
studies have shown almost complete resolution of symptoms after biofeedback
(muscular and thermal), relaxation training and hypnotic imagery (Barowsky et al.,
1987; Blanchard, 1979; Gainer, 1992). These approaches often target the learned
limb disuse that patients develop. Clinical experiences suggest that using the above
techniques in an integrated multidisciplinary context can provide substantial relief of
symptoms.

1.4.5 Implanted Therapies
In addition to traditional interventional therapies, advanced pain medicine
techniques used in the treatment of CRPS include spinal cord stimulation (SCS),
peripheral nerve stimulation (PNS), and intrathecal drug delivery (ITDD). These
implantable modalities are more commonly used for CRPS conditions that do not
respond appropriately to pharmacotherapy, regional nerve blocks or physical
therapy.

1.4.5.1 Spinal Cord Stimulation
Nerve stimulation (either spinal cord or peripheral nerve) was first suggested
for use in pain in 1967 (Shealy, Mortimer, et al., 1967; Shealy, Taslitz, et al., 1967).
SCS was performed by Cook et al (1976) for pain relief of secondary ischemia to
peripheral vascular disease (Cook et al., 1976). It was also found to improve
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perfusion after Jacobs et al (1988) showed relief of ischemic leg pain and
improvement of ulcer healing (Jacobs et al., 1988). SCS is performed by the
implantation (either temporary or permanent) of small, soft wires near the spinal
cord. These wires have electrical leads on their tips that pass electrical currents that
are produced by a small programmable generator often surgically placed under the
skin of the buttocks or abdomen. Neurostimulation in this manner blocks pain signals
by applying a mild electrical current to the spinal cord (SC), often resulting in less
pain and a tingling feeling in the affected area called paresthesia (Wilson et al.,
2005); however, the exact mechanisms by which SCS relieves pain is still not fully
understood. It was originally though to target the dorsal column of the SC but other
studies showed that neurostimulation also influenced transmission (affecting sensory
dorsal nerves and descending inhibitory pathways in the SC) (Linderoth et al., 1992;
Long et al., 1981). It is also thought that the improved peripheral circulation after SC
stimulation is the result of autonomic effects as the neurostimulation may modulate
efferent impulses that could produce vasodilation in the innervated dermatome
(Wilson et al., 2005).

1.4.5.2 Peripheral Nerve Stimulation (PNS)
PNS works in a similar manner to SCS:,small electrodes are placed along
peripheral nerves in the targeted limb and often cause a reduction in pain, as well as
the same paresthesia observed in SCS (Wilson et al., 2005). PNS can be used
alone, but it is often used together with SCS. An indication for this type of treatment
is pain predominating in a region innervated by only one peripheral nerve. In both
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SCS and PNS, nerve stimulation is temporarily tested to allow for patient feedback
before any permanent surgical implant is in place (Wilson et al., 2005). Although
there are limited randomized studies examining this treatment, pain relief has been
demonstrated in several retrospective studies (Ebel et al., 2000; Law et al., 1980).

1.4.5.3 Intrathecal Drug Delivery
	
  
ITDD is a complex technique involving the implantation of infusion pumps that
deliver pharmacological agents directly to a site on the spinal cord (Wilson et al.,
2005). The intrathecal pump, sometimes called the “pain pump”, has been typically
used for patients with cancer pain (Onofrio et al., 1981); however, CRPS patients in
several case studies have found pain relief from this technique. Medication is
delivered via small catheters that originate in a small pump surgically implanted
under the skin of the abdomen (Institute, 2013). Typically, morphine is the first-line
agent used in ITDD. Morphine administered via intrathecal pump has been reported
effective several times, especially in severe cases of CRPS.
There are limitations to ITDD. Similar to other opioid treatments, dose
increases are usually required. Complications with the catheter tip exist, where tip
masses can form when medication is delivered at high concentration (McMillan et
al., 2003). Finally, kinking of the catheter often causes a mild red rash on the skin
and jeopardizes the integrity of the catheter (Wilson et al., 2005).
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1.4.6 Other Therapeutic Approaches
Several techniques are either not approved or have limited evidence to
support their use; a sample of these approaches are briefly addressed in this section
below.
In consideration of the tissue hypoxia and acidosis that often accompanies
CRPS, Kiralp et al, Tuter et al and Peach all proposed the use of hyperbaric oxygen
(HBO) therapy (Kiralp et al., 2004; Peach, 1995; Tuter et al., 1997). In a randomized,
placebo-controlled study, Kiralp demonstrated the use of HBO therapy in markedly
attenuating edema and pain in CRPS patients after 15 treatments; these findings
lend additional support to warrant further research of HBO therapy and for
treatments targeting edema and hypoxia for pain relief.
Traditional Chinese medicine involves qigong, a concept with growing
popularity in North America that focuses on balancing one’s “life energy”. Recently,
its use has been examined for therapeutic benefits in many conditions ranging from
cancer and pain, to obesity and hypertension (Bao et al., 2014; Elder et al., 2007;
Xiong et al., 2015). Although there are some clinical studies suggesting qigong as a
potential treatment for CRPS-I (Lee et al., 2007; W. H. Wu et al., 1999), the small
number of participants involved precludes any solid conclusion. Further research
may be warranted for its use in resolving depression, anxiety and other psychiatric
complications resulting from CRPS diagnosis.
One event known to trigger CRPS complications is surgery. Casting and
tourniquet use have been suggested as possible initiating noxious events for CRPS.
A preventative, rather than therapeutic, approach to CRPS has been studied for
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surgical cases by using vitamin C. One-gram daily of vitamin C treatment was found
to be effective at preventing CRPS after both upper and lower limb surgery (Besse
et al., 2009; Zollinger et al., 1999). More recently, Vitamin C was found to have an
antiallodynic effect in rats, when delivered once per day for 3 days before a hindpaw
ischemia-reperfusion injury was induced (the chronic post-ischemia pain model
(CPIP) (Park et al., 2013). Co-administration with vitamin E had a greater
antiallodynic effect in the experiment, and together these vitamins were suggested
as modulators of spinal cord neuropathic pain processing.
A relatively radical approach to CRPS is a ketamine coma, where extended
use of anesthetic dosages of ketamine is used to place a CRPS patient in a coma.
Ketamine has been found to reduce pain significantly is many patients when applied
topically or by IV; however, the ketamine coma has been suggested to reset NMDA
receptors and block the central sensitization existing in CRPS (Henson & Bruehl,
2010). Studies examining its use are limited and the treatment is still considered
controversial and unproven in Canada.
A common theme in the discussion of most therapeutic approaches for CRPS
is that further study is required. Many studies lack quality controls or a large sample
size to confidently state conclusions. Clinical trials on both CRPS patients and those
at risk of developing CRPS (e.g., receiving knee replacement surgery) is to assess
the efficacy of various treatments and to better understand the best multi-disciplinary
approach to treating CRPS.
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1.5 PATHOPHYSIOLOGY
Current knowledge of the pathophysiologic mechanisms driving CRPS
symptoms suggests they are multifactorial. A recent comprehensive review by
Bruehl (2010) presents a summary of the most widely accepted and documented
pathophysiologic mechanisms that may contribute to CRPS; they include peripheral
and central nervous system sensitization, inflammation (increased pro-inflammatory
cytokines and decreased anti-inflammatory cytokines), altered sympathetic and
catecholaminergic function, altered somatosensory representation in the brain,
genetic factors and psychophysiologic interactions (Bruehl, 2010). It is now clear that
the above multiple mechanisms are involved, and that CRPS presentation depends
on the relative contribution of each mechanism.
The majority of CRPS patients have a clinical history of some noxious injury
(trauma, ischemia, nerve injury) that initiates their symptoms. Often, as a result,
clinicians observe signs of inflammation (e.g. edema, redness and hyperemia).
Increased local and systemic levels of pro-inflammatory cytokines (e.g. TNF-alpha,
IL-1beta, IL-2 and IL-6) have been observed and correlated with CRPS symptoms in
patients (Maihofner et al., 2005; Uceyler et al., 2007). Decreased anti-inflammatory
cytokines (e.g. IL-10) are observed in CRPS patients as well (Uceyler et al., 2007).
Pro-inflammatory cytokines are released after trauma by classical inflammatory
mechanisms, by action of immune cells (lymphocytes, mast cells, etc); the effect of
is plasma extravasation, and subsequently edema, which probably explains the
edema and swelling often observed in CRPS patients. In addition to proinflammatory cytokines, neuropeptides Substance P and calcitonin gene-related
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peptide (CGRP) can trigger neurogenic inflammation (Bruehl, 2010). Neuropeptides
and pro-inflammatory cytokines have also been found to produce peripheral nerve
sensitization, leading to increased nociception (Bruehl, 2010). These molecules
have also been found to stimulate osteoclasts, explaining the osteoporosis
frequently observed in CRPS patients (Birklein & Schmelz, 2008).
Sensitization of peripheral nerves, which leads to persistent pain, is triggered
by the initial tissue trauma and inflammation as explained above and is present early
in CRPS symptomatology. After trauma, release of neuropeptides and inflammatory
cytokines can increase background firing of nociceptors and decrease the firing
threshold for mechanical and thermal stimuli, resulting in allodynia and hyperalgesia
observed in CRPS patients (Bruehl, 2010; J. Cheng & Ji, 2008; Couture, 2001).
Central sensitization is the increased excitability of nociceptive neurons in the spinal
cord, often resulting from persistent noxious input after tissue damage or nerve
injury (Bruehl, 2010). Sensitization of the central nociceptors is often controlled
through neuropeptides and at N-methyl-D-aspartate (NMDA) receptors, leading to
extremely amplified responses to noxious stimuli (hyperalgesia) as well as to nonpainful stimuli (allodynia) (Bruehl, 2010; Gracely, 1992; Gracely et al., 1992).
Reduced cutaneous innervation of the affected limb has also been observed
in CRPS patients. Although CRPS-I has no clinical signs of nerve injury, Albrecht
and colleagues observed a reduced density of nerve fibres (both C- and A-delta
fibres) in the affect limbs of CRPS-I patients (Albrecht et al., 2006). No causative
role in the development of further CRPS symptoms has been proven; however,
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needle stick injury in rodents to distal nerves has resulted in the development of
similar symptoms to CRPS-I patients (Albrecht et al., 2006; Siegel et al., 2007b).
Altered sympathetic nervous system (SNS) function has historically been
linked to CRPS, as classical symptoms include ‘cool’ and ‘blue’ affected limbs,
caused by vasoconstriction from SNS outflow. It is believed that pain in some CRPS
cases is sympathetically maintained, meaning that there is excessive SNS outflow
that results in pain. Sympathetic nerve blocks as a treatment option directly arose
from this ideology. Studies in rodents have found that increased adrenergic
receptors are expressed on nociceptive nerve fibres after trauma, perhaps
explaining why nociceptive signals are triggered (Janig & Baron, 2002). The receptor
expression may be linked to sympatho-afferent coupling, which results in
sympathetic nerve activity stimulating these receptors on nociceptive fibres. Afferent
nociceptive fibres become sensitized to adrenergic excitation, leading to increased
firing in the presence of sympathetic outflow or circulating catecholamines. (Arnold &
Delbos, 2003; Baron & Maier, 1996; Harden et al., 1994; H. A. Kurvers, 1998). The
persistent activation leads to sensitization of the central nervous system as well.
Hypofunction of the SNS directly after injury is believed to upregulate the
expression of peripheral catecholaminergic receptors, resulting in supersensitivity to
circulating catecholamines, causing vasoconstriction (Birklein et al., 1998; Harden et
al., 1994; H. Kurvers et al., 1998). Despite a lower level of catecholamines in the
affected limb of CRPS patients, vasoconstriction is observed; this is probably the
result of sensitization of peripheral adrenergic receptors during the acute phase of
CRPS (Bruehl, 2010). Therefore, vasoconstriction may still occur even with

	
  

	
  

30

decreased local sympathetic outflow. The sensitization of adrenergic receptors also
explains the exaggerated sweating and vasoconstriction observed after exposure to
circulating catecholamines. Catecholamines can increase in the event of regular life
stress or pain sensations. An odd vicious cycle may occur where catecholamine
release leads to nociceptive input, maintaining an altered central process that
generates more pain, and subsequently more catecholamine release (Wilson et al.,
2005).
There are limited studies examining CRPS using imaging techniques,
however one review of neuroimaging literature has concluded that there is little
evidence supporting the concept of a “pain network” in neuropathic pain syndromes
(Moisset & Bouhassira, 2007). After acute pain experiments, researchers have been
able to correlate activity in specific areas of the brain with various experimental
stimuli inducing pain; however, brain activity as a result of clinical pain, more
specifically chronic pain, is not well understood and does not correlate well with the
“pain network” or “pain matrix” characterized after inducing experimental pain. Also,
there is no evidence for a consistent brain activation pattern associated with
allodynia. All of this considered, there have been several studies of CRPS using
neuroimaging

techniques

that

observe

one

consistent

brain

alteration:

a

reorganization of the somatotopic map. More specifically, the alteration is a
reduction in the size of the representation of the affected limb in the somatosensory
cortex (Juottonen et al., 2002; Maihofner et al., 2003). The degree of this brain
plasticity has been directly correlated to the level of hyperalgesia, as well as CRPS
pain intensity (Bruehl, 2010; Maihofner et al., 2003). Somatotopic reorganization in
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CRPS patients has also been linked to impaired sensory perception, like the ability
to discriminate between two-point tactile stimulation. Although it is not known when
in CRPS development the reduced limb representation occurs in the brain, these
findings have clinical importance and reflect the multifaceted nature of CRPS.
Genetic factors have been suggested to play a role in CRPS. Small sample
studies have correlated CRPS development with a familial link. Onset of CRPS in
siblings of CRPS patients occurs 3-times as often as non-familial cases (de Rooij et
al., 2009). Genes involved with major histocompatibility complex encoding the
human leukocyte antigen (HLA) molecule, and genes involved in inflammation (like a
TNF-alpha promoter gene) have been thought to play a role in CRPS development
(Vaneker et al., 2005). A polymorphism of the TNF-alpha promoter gene has been
suggested to increase TNF-alpha levels, perhaps contributing to the exaggerated
inflammatory response observed in CRPS patients. The hypothesis that genetic
factors play a role in CRPS development is still being assessed, and no study has
provided evidence from a large sample size to link the two.
A psychological cause for the development of CRPS has been hypothesized
since the syndrome was formally recognized; today, some still continue to hold this
idea (Ochoa & Verdugo, 1995). The literature currently holds very few strong
prospective studies examining this hypothesis, although theoretically it is possible
that psychophysiological mechanisms may contribute to the development of CRPS
(Bruehl, 2010). However, psychogenic factors alone are not sufficient to produce the
signs of CRPS. One study by Harden et al (2003) found that higher anxiety levels
before total knee arthroplasty surgery were associated with a greater likelihood of
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being diagnosed with CRPS by 1-month post-procedure (Harden et al., 2003). This
may be related to the increase in catecholamine activity observed during
psychological distress (Charney et al., 1990; Harden et al., 2004), potentially
contributing to the adrenergic mechanisms involved in CRPS (Bruehl, 2010).
Although there are theoretical links and a few prospective studies that suggest
psychological factors impact on the development of CRPS, further prospective work
is required to provide any empirical evidence.
No empirical studies have been performed evaluating the interactions
between many of the pathophysiological mechanisms described above; however,
Bruehl (2010) described a speculative model of how these mechanisms may come
together in CRPS development and maintenance (Bruehl, 2010). His model is
illustrated in Figure 1.1. CRPS is clearly multifaceted in its pathophysiologic
mechanisms, and further studies are required to comprehensively evaluate the
contribution of each mechanism to CRPS signs and symptoms. Considering that
mechanism-based treatment is a goal in CRPS therapy, our lack of understanding
the pathophysiology is detrimental not only to patients and the healthcare system,
but arguably also to our economy, since many CRPS patients are unable to work.
Further research into identifying pathophysiologic mechanisms may eventually
permit the development of effective clinical treatment options and, perhaps, a “cure”.
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Figure 1.1. Speculative contributions of pathophysiologic mechanisms in CRPS
Adapted from Bruehl 2010.
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1.6 ANIMAL MODELS OF CRPS-I
Limited in number, there have been several attempts to model CRPS-I in
small animals. Compared with CRPS-II animal models, which have been well
characterized through the use of nerve injury, the key to developing a CRPS-I
animal model has been the induction of neuropathic-like pain without initiating a
major nerve injury.
One of the first animal models describing CRPS-I symptomatology was
developed by van der Laan et al (van der Laan et al., 1997). It involved the
administration of a free-radical donor called tert-butyl-hyperperoxide into the femoral
artery of conscious rats for 24 hours. The result was mechanical allodynia, lasting for
at least 4 weeks. The authors hypothesized that free-radical application triggered a
sensitization of both peripheral nerves and central processing and subsequently, the
hyperalgesia and allodynia (van der Laan et al., 1997). Plasma extravasation and
significant inflammatory signs (redness, increased temperature and edema) were
also observed. After treatment with a free-radical scavenger before and after injury,
the authors found significantly altered effects. While this model presented a very
interesting attempt at modelling CRPS-I, no further studies have been done.
Another model, developed in 1998 by Vatine et al, used electrical stimulation
of the sciatic nerve to initiate hyperalgesia and allodynia (Vatine et al., 1998). The
authors applied a 0.5 Hz and 8mA electrical stimulation to the sciatic nerve
supramaximally for 10 minutes and found that animals developed significant thermal
hyperalgesia, as well as some cold and mechanical allodynia symptoms. They
hypothesized that sensory changes were due to sensitization of the nerve or its
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central connections, and not a nerve injury. Symptoms normally observed in CRPS-I
patients, like swelling, redness and dystrophy, were not observed, thus no follow-up
studies were conducted.
Inducing signs of mechanical allodynia, ischemia and inflammation, Gradl et
al (2005) developed a CRPS-I animal model initiated by a controlled-impact softtissue injury and intra-arterial infusion of inflammatory mediators (Gradl et al., 2005).
The authors found that mechanical allodynia and local inflammatory effects were
triggered after intra-arterial infusion of Substance P for 24 hours. This model
presents an interesting method for initiating CRPS-I-like symptoms; however,
behavioural observations were only followed for four days post-injury and there was
no evidence of hyperalgesia or spontaneous pain behaviours.
A study by Oaklander et al (2006) showed evidence for minor nerve injury in
CRPS-I patients, suggesting that minor nerve injury may induce CRPS
symptomatology (Oaklander et al., 2006). Complementing these findings, Siegel et
al (2007) developed a novel model of CRPS-I by initiating a minor nerve injury of the
tibial or sural nerve using needle puncture (Siegel et al., 2007a). After nerve injury,
30-50% of rats developed mechanical allodynia that lasted 14-days post-injury, with
mechanical hyperalgesia and cold allodynia also evident in some rats. Interestingly,
there was no correlation between sensory changes and needle size used to initiate
injury, and there was no difference in sensory changes between tibial or sural minor
nerve injuries.
Perhaps a more clinically relevant model that those listed above, Guo et al
(2004) induced a number of CRPS-I signs and symptoms after initiating a rat tibial

	
  

	
  

36

fracture and casting for four weeks (Guo et al., 2004). Around 31% of CRPS cases
may indeed by the result of distal tibial fractures (Sarangi et al., 1993). After fracture
and casting, animals developed mechanical allodynia that lasted 16 weeks, as well
as edema and hyperthermia. Increased cytokines in the hind paw skin and
decreased mineral bone density was also observed. After glucocorticoid treatment,
edema and hyperthermia were attenuated; however, mechanical allodynia wasn’t
affected. After application of a neurokinin-1 (NK-1) antagonist and soluble TNFalpha receptor, mechanical allodynia was reversed, suggesting that Substance P
and TNF-alpha may play important roles in CRPS-I symptomatology.
The above-mentioned rat models each possess some features similar to
CRPS symptoms. As mentioned by Wilson and colleagues (2005), there is a need
for validation of existing standards and the generation of new models that can
recapitulate CRPS’s unique features (Wilson et al., 2005). Each animal model briefly
explained above lacks in representing most symptoms of CRPS. Thus, a chronic
post-ischemia pain (CPIP) model developed by Coderre et al (2004) through
ischemia-reperfusion injury may represent the literature’s best option for the study of
CRPS-I (Coderre et al., 2004).
1.6.1 CPIP Model
Coderre et al (2004) was able to produce a neuropathic pain-like syndrome in
rats after initiating a reperfusion injury due to prolonged hindpaw ischemia. In this
model, anesthetised rats were subjected to complete ischemia of one hindpaw,
through use of a tight fitting ring, for 3 hours. Hyperalgesia to noxious mechanical
stimuli and cold, as well as mechanical allodynia were evident and lasted for at least

	
  

	
  

37

four weeks post injury in most animals. Spontaneous pain behaviours, such as
licking, shaking and favouring of the hindpaw were also observed. Spread of
hyperalgesia and allodynia to the contralateral limb were also observed, similar to
the spread of symptoms in CRPS-I patients. In addition to sensory changes, rats
exhibited hyperemia and edema for several hours post-injury, all without ischemiainduced damage to the tibial nerve (Coderre et al., 2004).
CPIP presents a good tool for CRPS study as it displays several symptoms
that are observed in CRPS patients (Janig & Baron, 2002; van der Laan et al.,
1998). Considering CRPS is most common after fracture, sprain, crush injury and
surgery (i.e physical injury), this model is clinically relevant as it induces symptoms
through physical injury: ischemia-reperfusion. This model has been used several
times in the literature in order to assess the effect of different analgesic/anti-allodynic
treatments (Laferriere et al,. 2014; Nahm et al., 2014; Kwak et al., 2011; de Mos et
al., 2009).
Coderre and colleagues propose that many cases of CRPS-I are the result of
microcirculatory abnormalities following IR and persistent inflammation from injury.
Ischemia-reperfusion injury and inflammation can lead to a persistent state of
reduced perfusion and/or reduced oxygenation of tissue, which is likely involved in
the sensitization and activation of afferent innervation of the affected tissue (Coderre
et al., 2004). This activation and sensitization of muscle nociceptors would result in
deep, persistent pain, and can lead to the central sensitization that contributes to
mechanical allodynia and hyperalgesia. This means that chronic sensory
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disturbances present in CRPS-I patients may be strongly linked to the inflammatory
changes and microvascular deficits occurring after ischemia-reperfusion injury.
While CPIP provides evidence for the development of inflammatory and pain
symptoms after ischemia-reperfusion injury similar to CRPS-I, it would benefit from
functional analyses before and after injury, considering CRPS-I results in significant
functional deficits and behavioural changes in patients. Additionally, it may also
provide a proper means for the testing of other potential therapeutics.

1.7 HEME OXYGENASE
It may surprise many, but carbon monoxide (CO) – the so-called “silent killer”
gas – is endogenously produced in the body via the heme oxygenase (HO) system
during heme metabolism (Bauer et al., 2008). As displayed in Figure 1.2, heme from
hemoglobin is converted to biliverdin by HO enzyme, resulting in the formation of CO
and ferrous iron (Fe2+) byproducts (Kikuchi et al., 2005). Biliverdin is then quickly
converted to bilirubin through the biliverdin reducatase.
Heme oxygenase is present is three isoforms: HO-1, HO-2 and HO-3. HO-1,
which is in high abundance in the liver, spleen, vascular endothelial cells and
smooth muscle, is inducible in response to oxidative stress, hypoxia, heavy metals
and cytokines (Ryter & Otterbein, 2004; Ryter et al., 2002). HO-2 is constitutively
found and expressed under homeostatic conditions; it is found primarily in neuronal
cells, liver, heart, vascular endothelial cells and smooth muscle tissue (Maines,
1997). The function of HO-3 is not well understood.
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The HO system has often been associated with cytoprotective functions. The

anti-oxidant properties are evident in all byproducts of this system (Motterlini &
Foresti, 2014; Ryter et al., 2002). Both biliverdin and bilirubin have been found to be
potent scavengers of peroxyl radicals, as well as inhibiting the effect of other
mutagens (T. W. Wu et al., 1991). Ferrous iron, a byproduct of heme breakdown,
has also been found to reduce the formation of iron free radicals, contributing to the
cytoprotective effect of HO. Last, but definitely not least, CO is often regarded as
the most important player in the action of HO (Maines, 1997; Motterlini et al., 1998;
Otterbein et al., 1999). CO has been shown to be effective in diminishing the
severity of microvascular dysfunction after ischemia, as well as effective in reducing
inflammation and cell injury.
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Figure 1.2. Heme catabolism: conversion of heme to bilirubin through heme
oxygenase and biliverdin reductase, with carbon monoxide and iron as
byproducts.
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1.7.1 Carbon Monoxide
At normal conditions, CO exists as a colourless, tasteless and odourless gas
that is often the product of incomplete combustion (Varon et al., 1999). Currently, the
leading cause of death by poisoning in the United States is due to CO intoxication
(Meredith & Vale, 1988; Varon et al., 1999). Upon CO exposure, many detrimental
side effects may begin to appear, including headache, nausea, vomiting, impaired
memory, confusion and dizziness. Death is said to occur when carboxyhemoglobin
levels reach 50-80% (Burg, Ryter and Otterbein 2004).
Although there seems to be a number of reasons why carbon monoxide
should never be considered for use as a therapy, investigations into its uses in many
unique settings are currently underway and are showing promise for its potential as
a treatment in several conditions.
In 2001, Fujita and colleagues showed the paradoxical rescue of ischemic
lung tissue by CO in a HO-1 deficient murine model (Fujita et al., 2001). They found
that inhaled CO was able to potentiate fibrinolysis by suppressing the induction of
the gene encoding plasminogen activator inhibitor-1 in phagocytes. They concluded
that suppression of this hypoxia-induced protein was the result of action through
soluble guanylate cyclase (Fujita et al., 2001). From this work, and several other
from the late 1990’s and early 2000’s, the proposition of using CO in a clinical setting
in the future has been garnering attention.
In 2008, a review by Foresti and colleagues outlined the promises and
challenges associated with the use of CO in therapy. In examining inhaled CO, they
found that there were indeed several studies showing remarkable results in the
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treatment of inflammatory processes and cardiovascular disorders, in pre-clinical
models; however, they could not ignore the inherent toxic effects CO can produce if
uncontrolled amounts were delivered (Foresti et al., 2008). They concluded that
administration of gaseous compounds in a clinical setting would come with many
difficulties and potential complications; they suggested the use of carbon monoxidereleasing molecules (CO-RMs) would provide a much more clinically applicable
therapeutic option.

1.7.1.1 Inhaled CO
Exogenous application of CO through inhalation has been investigated in
several studies and has been shown to have beneficial effects (Fujita et al., 2001;
Mishra et al., 2006; Ott et al., 2005); however, CO toxicity is still a very serious and
potential risk. CO binds haemoglobin at approximately 220 times the strength
oxygen does (Motterlini, 2007). This significant difference in affinity poses potential
risks of reducing the oxygen-carrying capacity, resulting in hypoxia, or the formation
of carboxyhemoglobin (HbCO) molecules, resulting in CO-poisoning. Although the
level of CO delivered through inhalation could be minimized so as to reduce the
levels of HbCO, CO poisoning is poorly understood and cannot rely solely on HbCO
levels as indication of toxicity (Foresti et al., 2008). HbCO levels, however, are still
good markers to predict the amount of CO present in the body; literature states that
a proportion of 15-20% HbCO is not detrimental and is the biological threshold for
CO tolerance (Foresti et al., 2008). Beyond, or around, this biological threshold and
co-mediated injury is likely to occur in most.
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In examining the effect of inhaled CO on lung disease or injury, several

studies have showed positive effect. Otterbein and colleagues (1999) found inhaled
CO provided protection against hyperoxic lung injury; they were the first to suggest
anti-inflammatory and anti-apoptotic actions of CO (Otterbein et al., 1999). Beneficial
effects of inhaled CO were confirmed in models of allergen-induced asthma
(Chapman et al., 2001), lung transplantation (Song et al., 2003), oxidative lung injury
(Otterbein et al., 2003), and lung hypertension (Zuckerbraun et al., 2006).
Interestingly, Clayton and colleagues (2001) challenged this positive view of CO
effects in their study that showed no benefits after CO treatment (Clayton et al.,
2001).
Inhaled CO has provided benefit in systemic inflammation and the
cardiovascular system as well. In several in vitro and in vivo models, CO was able to
reduce the production of inflammatory cytokines TNF-alpha and interleukins. In a
lung transplantation model, inhaled CO was able to prevent ischemia-reperfusion
injury (Kohmoto et al., 2006). It was also found that administration of CO provided
full protection even in the absence of HO-1 (Otterbein, 2002).
Although inhaled CO provides remarkable benefits in several pre-clinical
models, its administration in a clinical setting may be very limited.

1.7.1.2 Carbon Monoxide-Releasing Molecules (CO-RMs)
As a result of the potential risks associated with inhaled CO therapy, a novel
class of transition metal carbonyl compounds have been developed, in order to
deliver exogenous CO through an oral or injectable route (Foresti et al., 2008;
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Motterlini et al., 2002; Motterlini, Mann, et al., 2005). Carbon monoxide-releasing
molecules (CO-RMs), have the general chemical formula M(CO)xLy, whereby “M” is
the transition metal, “x” the number of CO ligands and “y” the number of additional
ligands (Santos-Silva et al., 2011).
The first CO-RMs developed, CORM-1 and CORM-2, were lipid soluble, fastreleasing compounds (Figure 1.3).

CORM-1 and CORM-2 both have half-lives

equal to or less than one minute (Motterlini, Mann, et al., 2005). As a result of the
need for solubility in solutions like DMSO or ethanol, these CO-RMs proved difficult
to administer, as they are relatively inapplicable to biological solutions. Eventually, a
water-soluble ruthenium-based CO-RM, CORM-3, was developed.
CORM-3 (molecular formula Ru(CO)3Cl(glycinate), also a short half-life
compound, is stable at physiological conditions (pH 7.4, 37oC, aqueous solution).
With a half-life of approximately one minute, CORM-3 rapidly liberates CO through a
ligand substitution reaction (Motterlini, Mann, et al., 2005). Both CORM-3 and a
newer CO-RM called CORM-A1, are promising compounds for the use of CO-RMs
in therapy (Motterlini, Sawle, et al., 2005).
Newer CO-RMs have been developed as of late, such as CORM-368,
CORM-401,

CORM-371,

CORM-409,

and

CORM-313;

however,

limited

investigations have been completed in terms of their therapeutic properties. These
newly synthesized CO-RMs are manganese-containing compounds (rather than
ruthenium) and therefore may provide less risk as a potential drug.
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Figure 1.3. Chemical

structures

of

three

carbon

monoxide-releasing

molecules (CO-RMs). Adapted from (Gullotta et al., 2012).
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1.7.1.3 CORM-3
One of the key limitations of the first CO-RM molecules developed was its
solubility. Lipid soluble molecules tend to be more difficult to administer clinically and
are therefore less favourable. In order to confer solubility in aqueous solutions,
biochemists were able to add a glycine amino acid molecule to the metallic carbonyl
compound (Motterlini, Mann, et al., 2005). With this amino acid addition, the half-life
of the compound remained similar to CORM-1 and -2 at about 1 minute, assuming in
physiological solutions. Motterlini and colleagues were able to show positive results
for CORM-3’s ability to release CO molecules upon administration in a rat model and
provide beneficial vasodilation. By also showing that CORM-3 administration was
safe up to a concentration of 500 µM, Motterlini was able to meet all of the criteria
required for a potential clinical carrier for pharmaceutical carbon monoxide
(Motterlini, Mann, et al., 2005).
CORM-3 has been used in both in vivo and in vitro modelling of several
disorders: downregulation of inflammation, cardio-protective effects, anti-thrombotic
effects, effects on hypertension, bactericidal effects, effects on intraocular pressure,
nephrotoxicity, and pain. Evidence for beneficial effects of CORM-3 has been
described by many authors (Bani-Hani et al., 2006; Desmard et al., 2009; Failli et al.,
2012; Hervera et al., 2012; Lawendy et al., 2014; Mizuguchi et al., 2009; Sato et al.,
2001; Sawle et al., 2005; Stagni et al., 2009; Tayem et al., 2006; Urquhart et al.,
2007; Varadi et al., 2007).
The mechanism(s) by which CORM-3 acts are still relatively unknown. Some
scholars state that CORM-3 (and CO-RMs in general), may act differently than their
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inhalational counterpart (Gullotta et al., 2012); however, based on the evidence that
CO possesses beneficial functions in controlling vessel tone, apoptosis, cell
proliferation, platelet aggregation, inflammation, neurotransmission and ion channel
activation, most researchers agree that CO (including CORM-3-generated CO) act
through several different signalling pathways (Alberto & Motterlini, 2007; Motterlini et
al., 2003). Specifically, the effect of CO appears to be mediated by cyclic GMP
(cGMP), which is part of a soluble guanylate cyclase signalling cascade (Failli et al.,
2012; Foresti et al., 2004; Fujita et al., 2001). Another pathway by which CORM-3
has been stated to act is the mitogen-activated protein kinase (MAPK) (Chlopicki et
al., 2006; Mishra et al., 2006; Zhang et al., 2003). While both the soluble guanylate
cyclase and MAPK pathways are suggested to mediate CO action, other possible
targets may include calcium-activated potassium channels, cytochrome P450 or the
mitochondrial respiratory chain (Chlopicki et al., 2006).

1.7.2 CO and Pain
Studies investigating CO and CO-RMs have been strongly suggesting their
beneficial effects in multiple disorders; however, a question arises whether CO could
have an effect on pain and/or sensory disorders. In 2012, Hervera and colleagues
discovered that CORM-3-derived CO was able to reduce mechanical allodynia, as
well as thermal hyperalgesia and allodynia in sciatic injury in mice. They suggested
that CORM-3 might produce these effects through inhibition of nitric oxide (NO)
pathways and synthesis, as well as through inhibition of microglial activation,
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implicated in the initiation and maintenance of neuropathic pain (Hervera et al.,
2012; Watkins et al., 2001).
Several other studies have investigated the effects of CO in pain (Bijjem et
al., 2013; Hervera, Gou, et al., 2013; Hervera, Leanez, et al., 2013; Negrete et al.,
2014); however, none have examined the effect of CO on functional behaviour.

1.8

FUNCTIONAL TESTING AND CRPS
The clinical presentation of CRPS is dominated by a combination of sensory

and autonomic symptoms. However, mounting evidence indicates that many
patients with CRPS suffer from some forms of motor dysfunction and movement
disorders (Birklein et al., 2000; Schwartzman & Kerrigan, 1990; Veldman et al.,
1993). With the growing consensus being that movement disorders should be
included in the diagnostic criteria of CRPS, functional analysis is an area in need of
exploration.
Functional analysis can be performed through several methods. In rodent
models, however, there are two chief methods used to assess functional changes:
(1) electrophysiological testing and (2) locomotor analysis. In electrophysiological
testing, by using electrodes and isolated muscle, contraction amplitude and
frequencies can be measured and analyzed in comparison with the afferent
stimulation provided. These, however, do not reveal the true function of the limb.
Locomotion,

as

a

consequence

of

neurological

stimulation,

muscle

contraction and coordination between limbs, is a better measure of function in all
models. Several methods of locomotor analysis exist.
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Open field locomotion, was initially developed to examine behaviour of

rodents (Hall, 1934). It utilizes an open field apparatus to acquire locomotor
information through the capture of images, or through the use of infrared photocells.
Recently, open field locomotion analysis has begun to examine the use of infrared
illumination for capturing data, rather than visible light, which could interfere with an
animal’s behaviour (Aragao Rda et al., 2011). Although useful for examining some
behavioural and locomotor changes in the rat, these open field locomotion methods
are time-consuming and cannot measure some very important parameters of gait.
Other methods of locomotor analysis include the paper paw print method, the
electric grid method, as well as Cheng’s glass plate method (Afelt et al., 1983; Basso
et al., 1995; H. Cheng et al., 1997; de Medinaceli et al., 1982). Each of these,
however, has its own set of drawbacks and cannot provide a rapid and objective
means to examining a large set of gait parameters.

1.8.1 CatWalk™ Automated Gait Analysis
The CatWalk™ automated gait analysis system is a computerized functional
assessment tool for rats and mice, rapidly and objectively quantifying many
parameters of gait. The system has been validated in numerous animal models,
including spinal cord injuries (Koopmans et al., 2005; Miyagi et al., 2013), allodynia
(Gabriel et al., 2007; Vrinten & Hamers, 2003), sciatic nerve injury (Bozkurt et al.,
2008; Chiang et al., 2014) and arthritis (Angeby-Moller et al., 2008; Ferland et al.,
2011).
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This system uses a 1-metre long glass-floored walkway with a green light

source attached, such that the light is completely internally reflected in the glass.
Once a paw makes contact with the glass, light escapes and scatters; this can be
detected by a digital video camera fixed below. After videos are recorded, and each
paw print has been classified, the CatWalk™ software calculates static and dynamic
parameters of gait (Appendix A).
To ensure precision in acquiring data, rodents must be thoroughly trained
before the commencement of baseline tests. Ideally, rodents should be able to run
from one end of the walkway to the other in an un-interrupted fashion. Some factors,
however, may significantly alter gait parameters. Gabriel et al (2007) demonstrated
that a 40% body mass increase affects many gait parameters. It is therefore crucial
to the experiment to ensure rodents stay within a bracket of body mass.
In comparison with von Frey mechanical stimulation testing – the gold
standard test for measuring allodynia – Vrinten and Hamers (2003) demonstrated
that the CatWalk™ provided similar results, suggesting gait analysis may be a more
rapid, reproducible and objective tool for measuring allodynia.

1.8.2 Functional Testing in CRPS Patients
In examining and publicizing CRPS, pain is usually the main focus, and not
the disabilities that come with it. The pain is often so debilitating that joints become
locked, bones become osteoporotic and muscles become spastic and atrophy.
Disuse of the affected limb is a common feature of CRPS and is often the result of
patients trying to avoid potential painful stimuli. This can lead to skin changes (colour
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and temperature) as well as hyperalgesia (Butler, 2001). By avoiding the use of the
limb, patients may operant condition themselves, reinforced by the avoidance of
actual pain and even the reduced anxiety of anticipated pain. This would result in the
prevention of de-sensitization as well as the elimination of any tactile or
proprioceptive input that may help restore central signal processing of the limb (M.
Stanton-Hicks et al., 1998; H. K. Watson & Carlson, 1987). Disuse may also result in
a lack of natural blood pumping from limb musculature, perhaps resulting in an
accumulation of catecholamines or tachykinin that could further exacerbate CRPS
symptoms (Drummond et al., 2001; Weber et al., 2001).
As a result, Wilfrid Janig proposed several research directions towards
understanding the functional deficits associated with CRPS (Wilson et al., 2005). He
suggested the generation of new models that recapitulate the syndrome’s unique
features. The CPIP model mentioned earlier does indeed present several features
observed in CRPS patients; however, no study has been found to examine the
deficits accumulated through functional testing modalities like gait analysis.
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AIM OF THIS THESIS
Despite the breadth of work dedicated to understanding CRPS-I, there are

still several gaps in knowledge, and no cemented conclusion as to specific cause(s).
With recent studies observing microvascular deficits in CRPS-I patients (Bellingham
et al., 2014), the development of the CPIP model by Coderre et al has provided a
suitable avenue for the investigation of both pathophysiology and treatment options.
However, as suggested by Wilson et al (Wilson et al., 2005), future directions in the
study of this syndrome must be geared towards validation of existing models of
CRPS and generation of new models that recapitulate the unique features of this
syndrome; changes in gait and motor abnormalities are certainly unique features
that need to be assessed.
As a modulator of several signalling pathways that affect vascular properties,
CORM-3 may be a good potential treatment for vascular deficit disorders. With the
understanding that microvascular dysfunction may play an important role in the
development and maintenance of CRPS-I, the investigation into the use of CORM-3
as treatment of CRPS-I is warranted.
Therefore, the aim of this thesis was twofold: to examine the use of the
CatWalk™ automated gait analysis system in quantifying functional changes
following initiation of CRPS-like symptoms in the CPIP rodent model, and to
examine the potential therapeutic use of CORM-3 in CPIP.
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CHAPTER 2:

FUNCTIONAL ASSESSMENT OF ALLODYNIA IN A RAT
MODEL OF COMPLEX REGIONAL PAIN SYNDROME TYPE1 USING AUTOMATED GAIT ANALYSIS

2.1 INTRODUCTION
Complex regional pain syndrome type-1 (CRPS-I) is a debilitating chronic
pain condition, characterized by hyperalgesia and allodynia. Many studies suggest a
major factor in the development and maintenance of CRPS-I may be inflammation
and/or microcirculatory dysfunction (Albrecht et al., 2006; Bellingham et al., 2014;
Coderre & Bennett, 2010), while others suggest it to be a disease of the central
nervous system (Janig & Baron, 2002). Most clinicians however, prefer to believe
the syndrome to be multifactorial and is not driven by a single mechanism of injury
(Janig & Baron, 2006). Both of types I and II of CRPS develop after trauma and
present similar symptoms; however, CRPS-I occurs without nerve injury and the
severity of its symptoms are disproportionate to the severity of the trauma (Janig &
Baron, 2006).
A rodent model of CRPS-I, called chronic post-ischemia pain (CPIP),
developed by Coderre et al, induces microcirculatory dysfunction through ischemiareperfusion injury (Coderre et al., 2004). Consequent allodynia (mechanical and
cold), edema, hyperemia and hyperalgesia were observed to mimic those in patients
suffering from CRPS (Coderre et al., 2004; Harden et al., 2013; Janig & Baron,
2002; van der Laan et al., 1998; van der Laan et al., 1999). However, no objective
assessment of function was included in this model.

	
  

	
  

74
Automated gait analysis has been proposed to be a quality indicator of

behaviour and mechanical allodynia in many rodent pain and/or injury models
(CatWalk™). This computer-assisted technique allows for rapid quantification of
both static paw and dynamic inter-limb gait parameters (Angeby-Moller et al., 2008;
Bozkurt et al., 2008; Ferland et al., 2011; Gabriel et al., 2007; Gabriel et al., 2009;
Hamers et al., 2001; Huehnchen et al., 2013; Koopmans et al., 2005; Miyagi et al.,
2013; Sakuma et al., 2013; Vogelaar et al., 2004; Vrinten & Hamers, 2003).
Depending upon the model used, automated gait analysis has varying results as a
measure of allodynia.

In some chronic pain models (Gabriel et al., 2009), the

CatWalk™ system detected allodynia at different time points compared to standard
assessments of mechanical allodynia (the von Frey test, (Chaplan et al., 1994)), and
may also have understated measures of allodynia (Gabriel et al., 2009).
Alternatively, a study using carrageenan injections to induce neuropathic pain
provided significant correlation between CatWalk™ parameters and von Frey data
(Gabriel et al., 2007). Analysis of gait changes using the CatWalk™ system as a
measure of mechanical allodynia may be dependent on the model of chronic pain
being used (Gabriel et al., 2009). At this time, to our knowledge, there have been no
reports that examine the usefulness of the gait analysis to assess allodynia in the
CPIP model of CRPS-I. In addition, in keeping with the more stringent diagnostic
criteria for research purposes, functional tests should be required in many models.
Therefore, the purpose of this study was to investigate whether an automated
gait analysis system, the Catwalk™, would provide a more thorough and complete
assessment of allodynia in the CPIP model of CRPS-I.
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2.2 METHODS
2.2.1 Animal Description and Care
The experimental protocol was approved by the Canadian Council on Animal
Care at the University of Western Ontario. Animals were cared for in accordance to
the guidelines of the Committee for Research and Ethical Issues of the International
Association for the Study of Pain (IASP). All animals were housed in pairs with
access to food and water ad libitum.
Male Wistar rats (185 – 260 g) were anesthetized with inhalational isoflurane
(5% induction, 2% maintenance) in 1:1 oxygen/nitrogen gas mixture. Body
temperature was measured using a rectal probe thermometer and maintained at 37
degrees Celsius using a heating lamp. CPIP was generated by ischemia-reperfusion
(IR) injury of the right hind limb, as per Coderre et al (Coderre et al., 2004). Briefly,
ischemia was induced by application of tourniquet (#4 silk, Johnson and Johnson)
around the distal portion of the right hind limb, completely occluding the blood flow
(i.e. no-flow ischemia), and maintained for 3 hours. Reperfusion was initiated by a
tourniquet release. Tourniquet placement was at a standardized distance distal to
the tibial tuberosity of the distal portion of the hind limb, differing slightly from
tourniquet placement by Coderre and colleagues.
In a separate group of animals, the tourniquet was applied just proximal to the
knee joint (proximal IR group), so as to induce ischemia over the entire lower aspect
of the limb. The position of each tourniquet was standardized to minimize variation in
injury.
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2.2.2 Experimental Groups
Rats were randomized into three groups: CPIP (n=9), proximal IR (n=5) and
sham (n=8). Compared with the CPIP group, the proximal IR group differed in the
location of where the ischemia-reperfusion injury was induced. Sham animals
underwent all procedures as the CPIP and proximal IR groups, but the tourniquet
was not tightened.

2.2.3 Mechanical Allodynia Testing
To assess mechanical allodynia, hindpaw withdrawal thresholds to von Frey
filament stimulation were measured. Animals were placed on a raised, mesh-floored
platform and covered with a transparent plastic box. Animals were left for a minimum
of 5-10 minutes to allow for familiarization to the new environment before
measurements were taken. The plantar surfaces of both right and left hind paws
were stimulated by von Frey filaments with calibrated bending forces (grams)
(Stoelting Co., Wood Dale, IL) in order to determine a 50% withdrawal response
threshold, similar to the method developed by Chaplan et al (Chaplan et al., 1994).
Filaments were applied 10 times each, in ascending strength (1.0 g to 15.0 g).
Withdrawal thresholds were determined by a positive response observed a minimum
of 5 times at a specific filament strength. Positive responses were recorded as a lift
or lick. Withdrawal thresholds were measured pre-injury, as well as 5, 7, 8, 9, 10 and
14 days post-injury.
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2.2.4 Functional Analysis of Gait
The CatWalkTM (Noldus Information System, Wageningen) is an automated
gait analysis system that delivers a large collection of gait parameters, including paw
print area, duty cycle, weight load, swing phase and step regularity index. Static gait
parameters, including paw prints and weight load, as well as dynamic parameters
like duty cycle, are automatically measured and calculated by the system software.
Definitions of each parameter are listed in Table 2.1.
The system consists of a glass plate platform illuminated with fluorescent
tube; when contact is made with the glass, light is reflected downwards toward a
high-definition camera, connected to a computer, where it is then interpreted by the
accompanying software.
In order to assess gait, animals were trained to walk the length of the glass
plate platform end-to-end, prior to the induction of ischemia. A minimum of five days
of training was conducted for each animal until each animal was competent at
walking the length of the platform without interruption. General, dynamic and pawspecific gait parameters were collected pre-injury, as well as 1, 5, 7, 8, 9, 10 and 14
days post-injury. At least 3 runs, that were uninterrupted and 1-3 seconds in
duration, were recorded for each trial.

2.2.5 Statistical Analysis
Using GraphPad Prism® software, repeated measures two-way analysis of
variance (ANOVA) was performed to assess differences in gait parameters, as well
as paw withdrawal thresholds, compared to baseline and control values.
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Table 2.1.

CatWalk™

automated

gait

analysis

tool

parameters

and

definitions. Static and dynamic gait parameters were collected and
assessed using the assisting software package. The parameters
discussed in the results section were those showing the largest
changes from baseline measurements.

Static Gait
Parameter
Paw Print Area
2

(mm )

Dynamic Gait
Parameter

Definition
Total area of glass plate

Duty Cycle

in contact with paw during

(%)

stance phase

Definition
Stance as a percentage
of step cycle
(=stance/step cycle)
Duration in seconds
between two

Paw Print Width
(mm)

Total width of paw print

Step Cycle

consecutive initial

(s)

contacts of the same
paw (stance + swing
phases)

Paw Print Length
(mm)

Stance Phase

Duration in seconds of

Duration

contact of paw with

(s)

glass plate

by light intensity. Weight

Swing Phase

Duration in seconds of

load is mean intensity

Duration

no contact of paw with

(arbitrary units, a.u) per

(s)

glass plate

Total length of paw print
Paw pressure is indicated

Weight Load
(a.u/pixel)

pixel
Number of normal step
Step Regularity
Index
(%)

sequence patterns
(NSSP) relative to the
total number of paw
placements (PP)
(=(NSSPx4)/PP x 100%

	
  

Swing Speed

Speed of the paw

(distance units/s)

during swing phase
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Bonferroni post-tests were also performed. To determine if CatWalk™ parameters
correlated with the gold standard paw withdrawal thresholds, Pearson correlation
coefficients were calculated. A p<0.05 was considered significant.

2.3 RESULTS
2.3.1 CPIP And Proximal IR
For almost the entire duration of ischemia, the right hind paw (ipsilateral) was
observed as cold and cyanotic in all animals. Directly after the removal of the
tourniquet, evidence of severe edema and hyperemia were observed. Rats
displayed spontaneous pain behaviours, such as shaking, licking and lifting of the
injured limb. In the CPIP group, by 14 days post-reperfusion injury, most animals
displayed a slightly atrophied and less robust right hind limb when compared to the
contralateral limb. Animals in the proximal IR group showed less substantial
changes in spontaneous pain behaviours over the duration of the experiment. Sham
animals displayed no spontaneous pain behaviours or changes in the appearance of
the right hind limb.

2.3.2 Mechanical Allodynia
Ischemia-reperfusion injury led to the development of mechanical allodynia in
both the CPIP and proximal IR groups, as demonstrated by decreased paw
withdrawal thresholds of the ipsilateral limbs (Figure 2.1). In the CPIP group, by 7
days post-reperfusion injury, paw withdrawal thresholds of the injured right hind limb
decreased to 2.444 ± 0.689 g, from 13.889 ± 0.735 g at baseline (p<0.001).
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Figure 2.1. Paw withdrawal thresholds (PWT) of the ipsilateral/right hindpaw.
PWTs were assessed using mechanical stimulation via von Frey
filaments and analyzed via two-way repeated measures ANOVA.
PWTs of the ipsilateral/right hindpaw showed significant differences in
both CPIP and proximal IR groups; however, only the CPIP group
displayed sustained differences over the entire time course. (* p<0.05
from proximal IR group, † p<0.05 from baseline) Error bars shown
represent the standard error of the mean (SEM).
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The right hind limb displayed reduced paw withdrawal thresholds throughout the
duration of examination. At 14 days post-reperfusion injury, paw withdrawal
thresholds were still significantly lower than baseline values (5.556 ± 0.801 g,
compared to 13.889 ± 0.735 g at baseline (p<0.05)). At 7 days post-reperfusion
injury the contralateral limb also displayed a mild, though not significant, reduction in
the paw withdrawal thresholds (12.444 ± 1.334 g in CPIP versus 13.889 ± 0.735 g at
baseline, n.s.) (Figure 2.2).
In the proximal IR group, ipsilateral paw withdrawal thresholds decreased
from 15.00 ± 0.00 g at baseline to 6.00 ± 1.265 g after ischemia-reperfusion injury
(p<0.05). Paw withdrawal thresholds of the contralateral limb did not significantly
change from baseline, similar to the CPIP group. Withdrawal thresholds of the
injured (ipsilateral) hind limb were restored, without intervention, to baseline levels
by 14 days post-injury (Figure 2.2).
Sham animals displayed no significant changes in paw withdrawal thresholds
for the duration of the experiment (data not shown).
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Figure 2.2. Paw

withdrawal

thresholds

14 days IR
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9 days IR

8 days IR

7 days IR
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5 days IR
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Baseline

Threshold (g)

15

(PWT)

of

the

contralateral/left

hindpaw. PWTs were assessed using mechanical stimulation via von
Frey filaments and analyzed via two-way repeated measures ANOVA.
No significant differences in paw withdrawal thresholds were observed
in the contralateral/left hindpaw. Error bars shown represent the
standard error of the mean (SEM).
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2.3.3 Functional Analysis of Gait
Automated gait analysis detected several alterations of gait parameters postreperfusion. Both static (paw print area, paw print width, paw print length and weight
load) and dynamic (duty cycle, stance phase and swing cycle) parameters markedly
changed by 24 hours post-reperfusion injury (Figures 2.3 to 2.7). Paw print area
decreased from the baseline of 56.18 ± 8.38 mm2 in CPIP and 76.27 ± 18.65 mm2 in
proximal IR group to 1.113 ± 0.77 mm2 and 4.834 ± 2.97 mm2, respectively, after 1
day reperfusion injury (p<0.05) (Figure 2.3). By 5 days post-injury, print area in the
proximal IR group was restored back to baseline values. At 14 days post-injury, print
area of the CPIP group was still significantly decreased, at 25.39 ± 5.305 mm2
(p<0.05).
Print length and width demonstrated very similar significant trends (Figures
2.4 and 2.5). Using the Pearson correlation coefficient, all paw print parameters in
the CPIP group displayed correlation with paw withdrawal threshold data (p<0.05).
Correlation data is shown in Table 2.2.
Duty cycle in the CPIP group decreased after injury from the baseline of 53.2
± 2.1% to 6.8 ± 4.5% at 1 day post-injury (p<0.05) (Figure 2.6). The change in duty
cycle was sustained throughout the course of the experiment (32.6 ± 4.2% at 14
days post-injury, p<0.05). Correlation with paw withdrawal thresholds, using the
Pearson correlation coefficient, was confirmed in the CPIP group (p<0.05).
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Figure 2.3. Paw print area of the right hindpaw (mm2) in CPIP, proximal IR
and sham groups. Print area was calculated using the CatWalk
system software and analyzed via two-way repeated measures
ANOVA. CPIP animals show significant difference from sham group
after ischemia-reperfusion injury for the duration of the experiment.
Print area of proximal IR animals restore to baseline quickly after
injury. († p<0.05 from proximal IR group, * p<0.05 from baseline) Error
bars shown represent the standard error of the mean (SEM).
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Figure 2.4. Paw print length of the right hindpaw (mm). After ischemiareperfusion injury, CPIP animals demonstrated substantially lower print
length than sham and proximal IR groups through the duration of
testing. († p<0.05 from proximal IR group, * p<0.05 from baseline) Print
area was calculated using the CatWalk system software and analyzed
via two-way repeated measures ANOVA. Error bars shown represent
the standard error of the mean (SEM).
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Figure 2.5. Paw print width of the right hindpaw (mm). Print width was
markedly lower in CPIP animals after ischemia-reperfusion injury
compared to proximal IR and sham animals. († p<0.05 from proximal
IR group, * p<0.05 from baseline) Print width was calculated using the
CatWalk system software and analyzed via two-way repeated
measures ANOVA. Error bars shown represent the standard error of
the mean (SEM).

	
  

	
  

87

†

Duty Cycle (%)

60

*

*

*

† † †

* * * *

†

*

40

CPIP
proximal IR
Sham

20

0

0 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Days post-injury

Figure 2.6. Changes in Duty Cycle (stance phase/swing phase + stance
phase). Duty cycle was calculated using the CatWalk system software
and analyzed via two-way repeated measures ANOVA. After injury,
duty cycle in CPIP animals was significantly different from both
proximal IR and sham animals, for the duration of the experiment. (†
p<0.05 from proximal IR group, * p<0.05 from baseline) Error bars
shown represent the standard error of the mean (SEM).
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Figure 2.7. Swing speed of the right hindpaw. Swing speed was calculated
using the CatWalk system software and analyzed via two-way
repeated measures ANOVA. CPIP animals demonstrated a smaller
swing speed than proximal IR and sham groups throughout
experiment; however, swing speed at 14 days post-injury was not
different from baseline speed in CPIP animals. († p<0.05 from proximal
IR group, * p<0.05 from baseline) Error bars shown represent the
standard error of the mean (SEM).
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Table 2.2.

Correlation

coefficients

comparing

gait

parameters

and

mechanical stimulation. Using the Pearson Correlation statistical test
in our GraphPad Prism software, we compared gait parameters with
the gold standard mechanical stimulation measurements for mechanic
allodynia.

Gait Parameters

p-value

Correlation Coeffecient

Duty Cycle

0.0019

0.8760

Paw Print Area

0.0001

0.9609

Paw Print Length

0.0015

0.8817

Paw Print Width

0.0011

0.9002

Step Regularity Index

0.2320

0.2700

Swing Speed

0.0654

0.5253
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Step regularity index decreased from 89.8 ± 4.3% at baseline to 11.7 ± 7.8%

(p<0.05) at 1 day after injury, however it was restored to baseline without
intervention by 9 days post-injury. At 14 days post-injury, regularity index returned to
89.3 ± 4.5%. No correlation was observed using the Pearson correlation coefficient.
Swing speed decreased from the pre-injury value of 1071.0 ± 82.7 mm/s to
215.1 ± 180.3 mm/s at 1 day after injury, (p<0.05), and increased back to 928.6
mm/s ± 77.39 by 14 days post-injury in the CPIP group. In the proximal IR group, the
swing speed decreased from the pre-injury value of 1242.6 ± 101.3 mm/s to 242.5 ±
159.6 mm/s at 1 day after injury and returned to 1556.2 ± 73.8 mm/s at 14 days
post-injury. Although significantly different from proximal IR and sham groups at 14
days post-injury, swing speed in CPIP animals was not markedly different from its
baseline value. Swing speed showed no correlation with von Frey data, as well.
(Figure 2.7)
Sham animals showed no significant changes in gait parameters throughout
the entire length of the experiment.

2.4 DISCUSSION
In the present study, we demonstrated the use of automated gait analysis
(CatWalk™) to rapidly and objectively quantify allodynia in the CPIP model of
CRPS-I. Four gait parameters proved to display results correlating with the gold
standard von Frey mechanical stimulation tests, which were paw length, width, and
area as well as duty cycle. Through successful validation with gait analysis, we have
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provided a more objective, practical and perhaps more clinically relevant model of
CRPS-I.
Sensitivity was substantially heightened and spontaneous pain behaviours
were observed after injury, resulting in symptoms similar to those presented in
patients with CRPS-I (Coderre et al., 2004). After comparing the distal tourniquet
placement to one placed proximal to the knee joint, paw withdrawal thresholds
confirmed that tourniquet placement in the CPIP animals produced chronic
mechanical allodynia symptoms, whereas proximal tourniquet placement resulted in
paw withdrawal thresholds returning to baseline levels by 14 days post-injury.
Although sensitivity did indeed increase with IR injury in the proximal IR group, these
symptoms were not long lasting. This suggests the CPIP model is more
representative of chronic pain symptoms of CRPS-I compared to the proximal IR
group. The proximal IR group was added in order to both examine chronic pain
symptoms using a different tourniquet placement, as well as to assess muscular
tissue injury in the rodent after ischemia-reperfusion injury; however, our results
indicate the proximal IR group does not display a chronic pain response.
Mechanical stimulation using von Frey filaments demonstrated a persistent
increase in sensitivity and symptoms of allodynia in the CPIP group. Correlating with
results from the development of the CPIP model (Coderre et al., 2004), paw
withdrawal threshold was significantly lower than that of the pre-injury. Although the
O-ring band used to initiate ischemia in the original model was not used, our use of a
ligature (#4 silk, Johnson & Johnson) showed similar results, suggesting that the
same tension was applied.
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Confirmation of the CPIP model through mechanical stimulation testing

(Coderre et al., 2004) allowed for comparison with and examination of gait analysis,
through the automated CatWalkTM method. After sensitivity and gait analysis, some
correlation in mechanical allodynia measurements was observed. The decrease and
sustainment of paw withdrawal thresholds observed after ischemia-reperfusion injury
confirm the CPIP model produces mechanical allodynia; changes in gait parameters,
correlating well with changes in paw withdrawal thresholds, also suggest that
animals experienced allodynia. Meanwhile, the proximal IR animals did not display
persistent or correlating gait parameter changes, which again suggests that the
CPIP model best displays CRPS-I symptoms. This is important as it demonstrates
that the automated gait system is indeed assessing changes as a result of allodynia
rather than muscle injury, which would likely be greater in those animals undergoing
IR injury with a proximally placed tourniquet. In the proximal IR group though,
standard error is greater in both mechanical stimulation and gait analyses, perhaps
suggesting more variable occlusion of blood flow and less standardization of injury.
Gait parameters showed significant changes through the 14-day testing
period. At one day post-injury, all gait parameters were significantly different than
those at baseline (i.e. pre-injury); however, only duty cycle and paw print parameters
(area, length and width) maintained the significant changes throughout the duration
of the experiment. The time of contact of one paw in one single stepcycle, defined as
the stance phase duration, can be directly related to pain perception in the rat;
therefore, duty cycle, which is the ratio of stance phase duration to stepcycle, has
been suggested to be the gait parameter most indicative of mechanical allodynia
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(Gabriel et al., 2009). Static paw print parameters such as area, width, and length,
also provide indication of potential pain symptoms, as it would be reasonable to
expect a reduction in paw use when said paw is experiencing pain symptoms.
Weight load did not show chronic changes in contrast to other gait parameters. This
suggests that even with similar loads placed on the limb, the limb use is functionally
different in the CPIP animals.
Slight differences in gait parameter values between the control and sham
group were observed, especially in static paw print parameters. Sham animals were
slightly lesser in mass (and as such, smaller in size) upon commencement of testing
which may explain these findings. No significant differences were observed in
dynamic gait parameters. This was expected, even with the slight differences in
mass between the groups, as it has been shown that a 40% variation in mass is
required for significant difference in paw print intensity to be observed (Gabriel et al.,
2009).
Although gait parameter changes and von Frey tests differed in their
assessment of mechanical allodynia, these may be explained through the
mechanisms underlying the responses observed. Reaction to von Frey filament
stimulation involves minimal central processing (Gabriel et al., 2009), whereas gait is
a centrally controlled daily activity that can be affected by several factors, including
pain (Jordan et al., 2008; MacKay-Lyons, 2002; Pearson, 2000). Since human
chronic pain conditions are also centrally processed, gait is relevant to human
experiences and therefore its analysis may be more clinically applicable. Pain and
allodynia are obvious factors that impact gait, but behaviours changes and

	
  

	
  

94

neurological and/or muscular tissue damage definitely have a role as well. In
relevant literature, reversible nerve damage is usually not evident until at least 3-4
hours of ischemia, and in the CPIP model publication by Coderre and colleagues, no
nerve injury was observed through light microscopy (Coderre et al., 2004) Although
muscle tissue damage may impact our gait measurements, our correlation data
suggests that the gait changes were significantly correlated with changes in
mechanical allodynia, according to our gold standard mechanical stimulation tests.
These markedly correlated changes are shown in Figure 2.2.
Validation of the CPIP model provides additional support for the notion of
microcirculatory dysfunction and inflammation may be part of the pathophysiology
driving CRPS-I signs and symptoms. A recent clinical study by Bellingham et al
observed a decrease in deep tissue oxygen saturation in CRPS-I patients using near
infrared spectroscopy, supporting the theory that deep tissue hypoxia is part of the
pathogenesis

behind

CRPS-I,

providing

more

validity

to

an

inflammation/microvasculature dysfunction-based CRPS-I model (Bellingham et al.,
2014).
As stated by Gabriel et al, the use of the CatWalk™ method for assessment
of mechanical allodynia needs to be carefully restricted to specific injury models
(Gabriel et al., 2009). This study, through comparison of von Frey test and
CatWalkTM analysis, suggests that functional examination of gait provides a powerful
additional tool for the study of mechanical allodynia in the CPIP model of CRPS-I.
Supplementation with the CatWalk™ system provides an additional significant
measure of function and can provide a more robust account of the pain experience
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in the rodent. Ultimately, comparing therapeutic interventions in the management of
CRPS-I is currently very difficult; the addition of objective, practical and functional
testing adds substantially to our ability to develop more effective therapies.
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CHAPTER 3:

Carbon Monoxide Reduces the Level of Allodynia in a
Rodent Model of Complex Regional Pain Syndrome Type-1

3.1 INTRODUCTION
Complex regional pain syndrome type-1 (CRPS-I) is a clinical condition where
disproportional symptoms of pain and mechanical allodynia are experienced after
distal extremity trauma (Bellingham et al., 2014; Harden, 2010; Sandroni et al.,
1998; P. Wilson et al., 2005; P. R. Wilson, 2010). Sprains, crush injuries, surgery
and fractures have all been known to lead to a CRPS-I diagnosis (Bean et al., 2014;
Harden, 2010; Sandroni et al., 1998).
Recently, studies by Coderre and colleagues have led to the development of
a rodent model of CRPS-I, through initiation of the “slow-flow/no-reflow”
phenomenon by ischemia-reperfusion (IR) injury, triggering chronic post-ischemia
pain and allodynia, similar to those observed in patients suffering from CRPS-I.
Studies suggest that the pain perceived by some CRPS-I patients may indeed be
the result of I-R injury and the subsequent inflammation developed as a result of
microcirculatory changes from the IR injury (Bellingham et al., 2014; Coderre &
Bennett, 2010; Coderre et al., 2004).

Another recent study has demonstrated

impaired tissue oxygen saturation in the hands of patients with CRPS-I,
demonstrating that deep tissue hypoxia and microvascular dysfunction are involved
in the pathogenesis (or at least maintenance) of CRPS-I (Bellingham et al., 2014).
Lately, attention has been directed to the potential use of carbon monoxide
(CO) in a clinical setting, despite the detrimental and deadly effects commonly
associated with it. As a byproduct of the heme oxygenase (HO) system, CO is
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endogenously produced at low doses and, along with HO-1, has been correlated to
either the degree of injury/disease or increased survival in a variety of syndromes
(Foresti et al., 2008).
Although the mechanisms of CO action are poorly understood, exogenous
application through inhalation has been shown to elicit protection against multiple
organ injury (MOI), inflammation, apoptosis, cell proliferation, vasoconstriction and
hypertension (Chapman et al., 2001; Foresti et al., 2008; Fujita et al., 2001; Mishra
et al., 2006; Otterbein et al., 1999; Song et al., 2003). However, CO application
through inhalation is a clinically challenging therapy as carboxyhemoglobin (HbCO)
levels increase quickly, possibly leading to hypoxia and further co-mediated injury
(Clayton et al., 2001). Recent developments have led to the production of COreleasing molecule-3 (CORM-3), which is a water soluble, quick-releasing transition
metal carbonyl capable of efficiently releasing CO in the bloodstream (Foresti et al.,
2008; Foresti et al., 2004; Yabluchanskiy et al., 2012). Compared with CO
inhalation, CORM-3 application does not significantly alter HbCO levels (Foresti et
al., 2008; Foresti et al., 2004; Yabluchanskiy et al., 2012).
The anti-inflammatory and vasodilatory actions of CO are perhaps the most
intriguing and potentially useful. Previous studies have shown that the inflammatory
reaction after IR injury is reduced after application of CORM-3 (Lawendy et al.,
2014). Inflammation and oxidative stress resulting from ischemic conditions appear
to be the underlying factors for several chronic pathologies. Recent work suggests
that microvascular dysfunction and inflammation may be factors contributing to the
development of one such pathology, CRPS-I (Bruehl, 2010).
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Previously, in order to investigate symptoms of CRPS-I, mechanical allodynia

has been assessed using mechanical stimulation via the von Frey method. This,
however, does not test the function of the affected limb. The ‘CatWalkTM’ automated
gait analysis system rapidly and objectively quantifies several parameters of gait and
has been shown to be a quality supplement to the von Frey method in some injury
models (Angeby-Moller et al., 2008; Bozkurt et al., 2008; Chiang et al., 2014;
Ferland et al., 2011; Gabriel et al., 2007; Sakuma et al., 2013; Vrinten & Hamers,
2003).
Through the use of a previously validated model of CRPS-I, the purpose of
this study was to examine the effects of CORM-3 on the symptoms of CRPS-I,
specifically on symptoms of allodynia.

3.2 METHODS
3.2.1 Animal Description and Care
The experimental protocol was approved by the Canadian Council on Animal
Care at the University of Western Ontario. Animals were cared for in accordance to
the guidelines of the Committee for Research and Ethical Issues of the International
Association for the Study of Pain (IASP). All animals were housed in pairs with
access to food and water ad libitum.
Male Wistar rats (185-260g) were anesthetized with inhalational isoflurane
(5% induction, 2% maintenance) in a 1:1 oxygen/nitrogen gas mixture.
Chronic post-ischemia pain (CPIP) was generated by ischemia-reperfusion
(IR) injury of the right hindpaw, as per Coderre et al (Coderre et al., 2004). A
tourniquet (#4 silk, Johnson and Johnson) was applied to the distal portion of the
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right hind limb in each animal, completely occluding the blood flow. Tourniquet
application was maintained for 3 hours. The position of each tourniquet was
standardized so as to minimize variation in injury, as stated above in Chapter 2.
Reperfusion was then initiated by release of the tourniquet.

3.2.2 CORM-3
CORM-3 has been synthesized by us, in accordance with previously
published methods (Lawendy et al., 2014; Motterlini & Otterbein, 2010). CORM-3, or
its inactive counterpart, iCORM-3, were administered to animals at a dose of
10mg/kg, given IP.

3.2.3 Experimental Groups
Twenty male Wistar rats were randomized into two groups: control group,
treated with iCORM-3 (n=9), and an experimental group, treated with CORM-3
(n=11). Both CORM-3 and iCORM-3 groups were administered their respective
injections at 7 days post-injury via intra-peritoneal injection.

3.2.4 Mechanical Allodynia Testing
To assess allodynia, hind paw withdrawal thresholds (PWT) to von Frey
filament stimulation were measured. Animals were placed on a raised, mesh-floored
platform and covered with a transparent plastic box. To allow for familiarization to
the new surroundings, animals were left for a minimum of 10 minutes before
measurements were taken. The plantar surfaces of both right and left hind paws
were stimulated with von Frey filaments (Stoelting Co., Wood Dale, IL) in order to
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determine a 50% withdrawal response threshold in accordance with similar
techniques found in literature (Bennett, 2010). Filaments were applied 10 times each
in ascending strength (1.0 g to 15.0 g). Withdrawal thresholds were determined by a
positive response, observed a minimum of 5 times, at a specific filament strength.
Positive responses were recorded as a lift or lick. Withdrawal thresholds were
measured pre-injury, as well as 5, 7 (pre- and post-injection), 8, 9, 10, and 14 days
post-reperfusion.

3.2.5 Functional Analysis of Gait
The CatWalkTM (Noldus Information System, Wageningen) is an automated
gait analysis system that delivers a large collection of gait parameters, including paw
print area, duty cycle, weight load, swing phase and step regularity index. Static gait
parameters, including paw prints and weight load, as well as dynamic parameters
like duty cycle, are automatically measured and calculated by the system software.
The system consists of a glass platform illuminated by a fluorescent tube;
when contact is made with the glass, light is reflected downwards toward a highdefinition camera, connected to a computer, where it is then interpreted by the
accompanying software.
In order to assess gait, animals were trained to walk the length of the glass
plate platform end-to-end, prior to the induction of ischemia. A minimum of five days
of training was conducted until each animal was competent at walking the length of
the platform without interruption. During training, animals were motivated to traverse
the walkway by the use of sweet treats. General, dynamic and paw-specific gait
parameters were collected pre-injury, as well as 1, 5, 7 (pre- and post-injection), 8,
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9, 10 and 14 days post-injury. Each trial had a minimum of 3 runs, and only runs 1-3
seconds in duration were accepted.

3.2.6 Intravital Video Microscopy (IVVM)
In some iCORM-3 (n=5) and CORM-3 (n=5) animals, microscopic evaluation
of skeletal muscle microcirculation was undertaken using intravital video microscopy
(IVVM).
The extensor digitorum longus (EDL) muscle was isolated and prepared, as
described previously (Lawendy et al., 2011; Potter et al., 1993). Briefly, the tibialis
anterior and lateral gastrocnemius muscles were divided through blunt dissection to
expose the EDL. A suture ligature was applied around the distal tendon of the EDL
and the tendon was then cut from its bony attachment in order to reflect the muscle
onto the microscope stage, with its arterial and venous blood flow intact. Once
prepared, animals were carefully placed on the stage of an inverted microscope
(Nikon Diaphot 300) and the EDL reflected onto a slide with saline bath containing
5µg/ml each of the fluorescent vital dyes bisbenzimide (BB; Ex. 343nm, Em. 483nm)
and ethidium bromide (EB; Ex. 482nm, Em. 616nm). As BB stains the nuclei of all
cells while EB stains the nuclei of only those cells with damaged cell membrane,
EB/BB ratio provided an index of tissue injury. A cover slip was then placed atop the
EDL. The temperature of the exposed muscle and the animal itself was maintained
at 37 degrees Celsius by the use of a heat lamp. Care was taken to minimize time
between EDL exposure and the first microscope recording.
The inverted microscope was connected to a charge-coupled device camera
(Dage-MTI VE1000), a time-date generator (WJ-810, Panasonic), as well as a
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computer. To provide appropriate white light illumination, flexible fibre-optic guides
were positioned above the EDL.
Microvascular perfusion and leukocytes within the post-capillary venules were
recorded by translumination with 20x and 40x objectives, respectively, in five
randomly chosen fields of view. Fluorescence microscopy was used to visualize the
BB and EB from the same fields of view that had been selected for the measurement
of capillary perfusion. At the conclusion of the experiment, rats were euthanized by
an overdose of isoflurane anesthetic agent.

3.2.7 Offline Video Analysis
3.2.7.1 Perfusion Analysis
Capillary perfusion was measured in each 60-second clip at 20x objective
(final magnification of 700x), as per previously validated methodology (Lawendy et
al., 2014). Perfusion was quantified by counting the number of continuouslyperfused (CPC), non-perfused (NPC) and intermittently perfused (IPC) capillaries
crossing 3 equidistant parallel lines drawn on the computer monitor, perpendicular to
the capillary axis. Capillaries with continuous flow were deemed CPC, those with
flow interrupted at any point during the 60-second clip were deemed IPC, and those
with no flow throughout the 60-second clip were deemed NPC. These values were
expressed as the percent of total capillaries per field of view.

3.2.7.2 Analysis of Leukocytes
Leukocyte activation, i.e. rolling and adherence, was measured in postcapillary venules at 40x objective (final magnification of 1400x). Thirty second clips
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from each 45 second recording were randomly chosen; the total number of rolling
and adherent leukocytes were measured during this time and expressed per 1000
µm2. Venular area was measured using ImageJ (NIH, Bethesda, MD). Adherent
leukocytes were defined as those cells remaining stationary over the entire duration
of the 30-second clip.

3.2.7.3 Injury Analysis
BB and EB are nuclear dyes; BB labels nuclei of all cells, as it is membranepermeable, while EB is membrane impermeable and therefore only stains cells with
injured (permeable) membranes. EB labeling cannot distinguish between cell injury
and cell death, as a wide range of injury may cause increased membrane
permeability. Tissue injury in the randomly chosen fields of view was assessed by
counting the number of EB- and BB-labelled nuclei, and expressed as EB/BB ratio.

3.2.8 Statistical Analysis
Repeated measures two-way analysis of variance (ANOVA), using GraphPad
Prism® software, was performed to assess differences in gait parameters, paw
withdrawal thresholds, tissue perfusion, muscle injury, leukocyte rolling and
leukocyte adherence between iCORM-3 and CORM-3-treated animals. Statistical
difference was defined at p<0.05; Bonferroni post-tests were also performed.
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3.3 RESULTS
3.3.1 CRPS-I Model
For the duration of ischemia, the right hind paw (ipsilateral) was observed as
cold and cyanotic in all animals. Directly after the removal of the tourniquet,
evidence of severe edema and hyperemia were observed. Upon recovery, rats
displayed spontaneous pain behaviours, such as shaking, licking, and lifting of the
injured limb. By 14 days post-reperfusion injury, most animals displayed an
atrophied and less robust right hind limb when compared to the contralateral limb.
Two animals did not develop CRPS-I like symptoms or display pain behaviours, and
hence were excluded from further analysis.

3.3.2 Mechanical Allodynia
Ischemia-reperfusion

injury

led

to

increased

tactile

sensitivity,

as

demonstrated by decreased paw withdrawal thresholds of both the ipsilateral and
contralateral limbs. By 7 days post-reperfusion injury, paw withdrawal thresholds of
the injured right hind limb decreased from 14.25±0.41g at baseline to 3.00±0.59g
(p<0.001) (Figure 3.1). At 7 days post-reperfusion injury, the left hind limb displayed
paw withdrawal thresholds at an average of 11.25±0.85g, compared to 14.25±0.41g
at baseline (p<0.05). (Figure 3.1)
In the right hind limb, paw withdrawal thresholds were significantly less than
baseline levels in the iCORM-3 group throughout the duration of the experiment.
However, in the experimental group, upon administration of CORM-3 at 7 days postreperfusion injury, accelerated restoration of paw withdrawal thresholds was
observed.
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Figure 3.1. The effect of ischemia-Reperfusion on paw withdrawal threshold
(PWT) of the ipsilateral/right and contralateral/left hindpaws.
PWTs were assessed using mechanical stimulation via von Frey
filaments. PWTs of both the ipsilateral/right and contralateral/left
hindpaw showed significant differences after reperfusion injury. (*
p<0.05 from iCORM-3, † p<0.05 from baseline). Error bars shown
represent the standard error of the mean (SEM).
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Compared to application of iCORM-3, application of CORM-3 significantly

increased paw withdrawal thresholds (6.636±0.96g versus 2.222g±0.49g, p<0.05) at
1 hour post-injection. By 7 days post-injection (14 days post-reperfusion injury), right
hind limb paw withdrawal thresholds of CORM-3-administered animals were
restored to baseline levels. (Figure 3.2).
In the left hind limb, restoration of paw withdrawal thresholds back to baseline
values was observed quickly without intervention. CORM-3 had no effect on the
contralateral limb.

3.3.3 Functional Analysis of Gait
Gait analysis using the CatWalkTM method detected several alterations of gait
parameters post-reperfusion injury. Both static and dynamic parameters of gait
dramatically changed by 24 hours post-reperfusion injury, including paw print
parameters, weight load, duty cycle, stance phase and swing cycle, among several
others. However, by 7 days post-injury, most gait parameters were restored to
baseline without intervention, with the exception of paw print parameters (area,
length and width) and duty cycle. Application of CORM-3 did not affect duty cycle,
resulting in no significant difference from baseline. Similarly, paw print length and
width showed no differences between CORM-3 and iCORM-3 injections. Paw print
area demonstrated a trend of an increased rate of restoration of print area after
application of CORM-3; however, no significance was achieved (Figure 3.3).
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Figure 3.2. The effect of CORM-3 on paw withdrawal threshold (PWT). CORM3 was administered at 7 days post-injury and PWTs were assessed via
mechanical stimulation testing at 1 hour post-injection, and at 1, 2, 3
and 7 days post-injection. PWTs of the ipsilateral/right hindpaw
displayed significant changes after CORM-3 injection. No changes in
PWTs were observed in the contralateral hindpaw of iCORM-3 and
CORM-3 animals. (* p<0.05 from iCORM-3, † p<0.05 from baseline).
Error bars shown represent the standard error of the mean (SEM).
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Figure 3.3. Paw print area of the right hindpaw (mm2). Paw print was calculated
using the automated gait analysis software tool. († p<0.05 from
baseline) Error bars shown represent the standard error of the mean
(SEM).
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3.3.4 Microcirculation
3.3.4.1 Muscle Perfusion
When compared to CORM-3 animals at 14 days, CPC of the EDL in CORM-3
animals were significantly increased when compared to iCORM-3 animals (87±1%
versus 77±3%, p<0.05) (Figure 3.4). No significant difference between IPC in the
CORM-3 and iCORM-3 animals was observed (3±1% versus 6±2%, n.s.).
There was no significant difference in NPC in CORM-3 animals compared to
iCORM-3 animals at 14 days post-reperfusion injury (10±1% versus 17±3%, n.s.),
although a trend for increased perfusion with CORM-3 was observed.

3.3.4.2 Activated Leukocytes
Decreased adherence of leukocytes was observed in CORM-3 animals when
compared to iCORM-3 animals (0.7836±0.116 leukocytes/1000µm2 in CORM-3
group versus 2.482±0.556 leukocytes/1000µm2 in iCORM-3 group, p<0.05). No
significant difference in rolling leukocytes within the EDL was observed (8.320 ±
1.807

leukocytes/30s/1000µm2 in CORM-3

group

versus

9.12

±

2.992

leukocytes/30s/1000µm2 in iCORM-3 group, n.s.) (Figure 3.5).

3.3.4.3 Injury
The level of cell injury was not significantly different between iCORM-3 and
CORM-3

animals

after

intervention.

Animals

administered

with

CORM-3

demonstrated a 0.3202±0.1229% level of injury, compared with 0.4588±0.1369%
(n.s.) in iCORM-3-treated animals (Figure 3.6).

	
  

	
  

113

*
100

CPC
IPC
NPC

% Total

75
50
25
0

iCORM-3

CORM-3

Figure 3.4. Skeletal muscle capillary perfusion. Values are expressed as a
percentage of the total number of capillaries per field of view within
EDL muscle. Significant difference in CPC was observed between
CORM-3 and iCORM-3 animals. (* p<0.05 from iCORM-3). No
statistical differences were observed in IPC or NPC between CORM-3
and iCORM-3 groups. Error bars shown represent the standard error of
the mean (SEM).
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Figure 3.5. Leukocyte activation (adherence and rolling) in post-capillary
venules of the extensor digitorum longus after IVVM. Significant
difference in the number of adherent leukocytes was observed
between iCORM-3 and CORM-3 animals. (* p<0.05 from iCORM-3).
Error bars shown represent the standard error of the mean (SEM).
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Figure 3.6. The effect of CORM-3 on cellular injury within the skeletal muscle.
The index of injury was assessed as the ratio of EB-labeled nuclei to
BB-labeled nuclei (EB/BB). No statistical difference was observed,
although there was a trend towards a decrease in CORM-3-treated
animals. Error bars shown represent the standard error of the mean
(SEM).
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3.4 DISCUSSION
The chronic post-ischemia pain model, established by Coderre et al (Coderre
et al., 2004) and validated with gait analysis, appeared to successfully model
symptoms of CRPS-I in the rat, allowing for a comprehensive examination of
possible therapeutic interventions. In the present study, we demonstrated the effect
of CORM-3 on the reduction of mechanical allodynia symptoms, as well as its antiinflammatory and vasodilatory action through direct observation of microcirculation.
Prolonged ischemia-reperfusion injury led to production of mechanical
allodynia in the injured, as well as the uninjured, rat hind limbs. Consistent with
previous results (Coderre et al., 2004), animals displayed reduced paw withdrawal
thresholds after injury. Although this CRPS-like symptom was observed in both hind
limbs, allodynia was much more pronounced in the ischemia-injured limb. In animals
treated with inactive CORM-3, the reduced paw withdrawal threshold was
maintained throughout the duration of the experiment; CORM-3 injection restored
paw withdrawal thresholds to baseline levels, demonstrating a reduction in the pain
sensation and tactile sensitivity. Previously, other CO-RMs, (i.e. CORM-2), have
shown to have similar anti-nociceptive effects, as demonstrated in nerve constriction
models and inflammation-based models (Hervera, Gou, et al., 2013; Negrete et al.,
2014). Unlike CORM-2, CORM-3 is water-soluble, making it more clinically relevant
therapeutic, if found to be effective.
While the mechanisms of CORM-3 actions are not fully understood, studies
suggest that some may involve the suppression of oxidizing compound production
and up-regulation of free radical scavengers (Mizuguchi et al., 2010; Patterson et al.,
2014). This is consistent with the idea that CRPS-I may be induced or maintained
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through free radical generation and inflammatory processes, as treatment with other
free radical scavengers also appeared to reduce mechanical allodynia symptoms
(Coderre et al., 2004). Thus, our data may also provide support for inflammatory and
microvascular dysfunction as important factors in the development and maintenance
of CRPS-I.
As suggested previously (Gabriel et al., 2007; Gabriel et al., 2009), the
functional limb assessment by the use of the CatWalkTM automated gait analysis
system may be limited to certain injury models. In the case of the CPIP as a model
of CRPS-I, we have previously identified certain gait parameters as being important
in the correlation between von Frey filament testing for allodynia and gait analysis.
These included several paw print parameters (length, width, area) and duty cycle. In
response

to

ischemia-reperfusion

injury,

some

gait

parameters

changed

significantly. Application of CORM-3 had no effect; however, there was a trend for
increased paw print measurements (Figure 3.3). Given that changes in gait are a
more complex measure of allodynia as compared to mechanical stimulation, it is
reasonable to assume that pain sensation might not have as dramatic an effect.
Previously, changes in CatWalkTM gait parameters have been observed after certain
treatments, however, these were delivered multiple times over the course of the
injury period (Koopmans et al., 2009), as opposed to a single injection of CORM-3 in
our study. Thus, potential changes in gait parameters in response to CPIP should be
explored in the future, with multiple dosing regimen.
It has been suggested that CRPS-I may be maintained by microcirculatory
abnormalities (Bellingham et al., 2014; Coderre et al., 2004; Millecamps & Coderre,
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2008). Consistent with this, our IVVM data in the CPIP model shows that the muscle
tissue in the allodynic limb appears to have clear microvascular deficiencies. In
response to CPIP, cell injury, leukocyte activation and capillary perfusion all show
significant changes from the control parameters of sham animals previously
published in ischemia studies (Potter et al., 1993). At 7 days post-injury, CORM-3
altered leukocyte adhesion within the post-capillary venules of the EDL (Figure 3.5).
Additionally, CORM-3 also appeared to alter the degree of capillary perfusion
(Figure 3.4). These results confirm the anti-inflammatory and vasodilatory actions of
CO (McCarter et al., 2004; Mizuguchi et al., 2009), perhaps providing reason for the
reduced pain sensation and the trend for restored gait. While not significant, there
was a trend towards a reduced tissue injury in CORM-3-treated animals (Figure 3.6).
Perfusion, which may be affected by leukocyte activity (Granger & Senchenkova,
2010), is an important factor in functional use of a tissue. Thus, increased tissue
perfusion may help to rationalize the observed trend towards restoration of gait
parameters. Delivery of CORM-3 at seven days post-reperfusion injury may give it
little opportunity to act to reduce cell injury, since circulating endothelial progenitor
cells may have repaired damaged endothelium within seven days.
Considering the effects of CORM-3-released CO on the observed changes of
IVVM parameters in CPIP, restoration of microvascular perfusion may underlie the
mechanism by which CORM-3-derived CO is able to alleviate allodynia symptoms.
Thus, given the notion of microvascular dysfunction as one of the important factors
in the development and maintenance of CRPS-I, improving capillary perfusion and
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reducing leukocyte activation could explain the significant difference in the
withdrawal thresholds of CORM-3-administered animals.
Previously, magnetic resonance spectroscopy has demonstrated that CRPS
patients have hypoxic muscles in the affected limbs, which causes difficulty in
regulating normal limb functions (Heerschap et al., 1993). Transcription factor NFκB,
which has been shown to be involved in ischemia, inflammation and sensitization
pathologies, appears to be potently inhibited by CO preconditioning (Sun et al.,
2008). Some studies have shown a direct link of NFκB to the development of
allodynia in the CPIP model; thus it has been suggested that NFκB may play a role
in the pathogenesis of CRPS-I (de Mos et al., 2009). Application of NFκB inhibitor
was able to relieve both mechanical and cold allodynia symptoms. Therefore, it
could be hypothesized that application of CORM-3 may interfere with this potential
pathogenic mechanism of CRPS-I.
Another molecule recently linked to CRPS-I pathogenesis is the inflammatory
cytokine TNF-alpha (Maihofner et al., 2005; Munnikes et al., 2005; Sabsovich et al.,
2008; Wesseldijk et al., 2008a, 2008b). Increasing evidence suggests that TNFalpha plays a critical role in the pathogenesis of altered pain sensation. Although it
has been previously shown that TNF-alpha returns to baseline levels quickly after a
reperfusion injury (Bihari et al., 2014), Kramer et al found elevated TNF-alpha levels
in the skin of affected limbs of CRPS-I compared to “normal” fracture and
osteoarthritis patients (Kramer et al., 2011). This local, but not systemic, increase in
TNF-alpha may be linked to the well-documented peripheral effects of TNF-alpha on
nociceptor sensitization (Julius & Basbaum, 2001).
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CORM-3 to block the release of TNF-alpha levels during reperfusion (Lawendy et
al., 2014), perhaps the substance acts to reduce allodynia sensation in CPIP model
through a reduction in TNF-alpha levels. Further molecular examination of harvested
tissue from these animals is required to explore this.
Inflammation of the vasa nervorum around peripheral nerves (neuritis) may
be involved in CPIP (Coderre & Bennett, 2008); this suggests that relief of the
inflammation may reduce pain symptoms associated with CRPS-I. Several other
studies have demonstrated CO-RMs to be effective in reducing allodynia in a chronic
sciatic nerve constriction model of neuropathic pain (Hervera, Gou, et al., 2013;
Hervera, Leanez, et al., 2013). Given the range of pain models where CO was able
to provide relief of symptoms (including both nerve constriction and inflammatory
pain), CORM-3-derived CO may play an active role in several pathways of pain
sensation, either directly or indirectly. However, further comprehensive study into
both CORM-3 mechanisms and pain sensation would be required.
Treatment options currently available for CRPS-I patients are relatively
extensive. One of the common treatments is a regional nerve block to the affected
limb; however, recent studies have shown that regional anesthesia does not
consistently block pain, especially in ischemic limbs (Kucera & Boezaart, 2014).
Considering the fact that many patients do not respond to the available treatment,
the development of additional therapeutic options for CRPS-I is needed. A holistic
interpretation of the results from mechanical stimulation testing, gait analysis and
IVVM suggests that CORM-3 reduces allodynia symptoms in the CPIP rodent model
of CRPS-I. Considering that pain is the most important factor in patients’ quality of

	
  

	
  

121

life, the reduction in sensitivity, even without significant changes in gait, after
administration of CORM-3 is still an important finding. Considering the antiinflammatory and vasodilatory actions of CO, the reduction in allodynia symptoms
after CORM-3 administration again suggests that CRPS-I may have some
microvascular abnormalities associated with the maintenance of its symptoms. Thus,
our data suggests that CO, along with its current potential application in several
other pathologies, may have clinical relevance as a therapeutic agent in CRPS-I.
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CHAPTER 4:

GENERAL DISCUSSION AND CONCLUSIONS

4.1 OVERVIEW OF RESULTS
4.1.1 CPIP Model
This thesis focuses on the assessment and potential treatment of CRPS-I,
using the chronic post-ischemia pain (CPIP) model. The model has proved to be a
reliable representation of many CRPS-I-like symptoms, acquired through an insult
known to often result in CRPS. In keeping with the proposed hypotheses for the
pathophysiology of CRPS-I, the CPIP model appears to present what is perhaps the
best animal model for examination of CRPS-I mechanisms and assessment of
potential treatments. Compared with others, CPIP provides the hallmark symptoms
of CRPS-I, including chronic hyperalgesia, allodynia (both cold and mechanical),
inflammatory signs and spontaneous pain behaviours. The results of this thesis also
show that the CPIP model produces behavioural and functional deficits similar to
those observed in CRPS-I.
4.1.2 Gait Analysis
Chapter 2 describes the use of an automated gait analysis system (the
CatWalkTM) to assess functional changes in the CPIP model.
The data showed that gait analysis using the CatWalkTM system was able to
detect an injury after ischemia-reperfusion injury. Four gait parameters (duty cycle
and the three paw print parameters) statistically correlated with the chronic allodynia
measurements taken via the gold standard of von Frey filament stimulation. While
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other gait parameters showed significant changes immediately after injury, most
normalized quickly to baseline by the end of our 14-day testing cycle.
In a separate group of animals, we showed that the CPIP model was an
effective model for the development of long-lasting allodynia symptoms. CPIP
animals maintained lower threshold of von Frey stimulation compared to the
proximal IR group, which received a similar IR insult, only proximal to where the
tourniquet had been placed in the CPIP group. The results validated the CPIP model
in its ability to develop chronic allodynia. Interestingly, the CPIP group showed that
the injury paradigm was not the major factor in affecting gait alterations; rather the
gait alterations were probably secondary to allodynia. However, the physiology of
tourniquet position just below the knee (both in this model and in general) is not well
defined, and this may affect a range of kinematic parameters.
Chapter 2 provides us with an objective method for assessing functional
changes in the CPIP model of CRPS-I. As stated by the new Budapest diagnostic
criteria for CRPS (Harden et al., 2007), functional assessment is beneficial in
examining symptomatology of CRPS. By providing an additional measure for the
total pain experience in the rat, we may be able to better test the effects of potential
therapeutics in the treatment of CRPS-I.

4.1.3 The Effect of CORM-3
CORM-3 has been found to have some anti-inflammatory, anti-apoptotic and
vasodilatory properties (Lawendy et al., 2014). Based on this, we aimed to examine
its use as a potential therapeutic agent in reduction of allodynia symptoms, as well
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as any gait changes observed in the CPIP model of CRPS-I. In Chapter 3, we
showed that CORM-3-derived CO carried anti-allodynic effects after an injection at
seven days post-reperfusion. We demonstrated that CORM-3 was able to increase
von Frey mechanical stimulation withdrawal threshold values back to baseline within
seven days post-injection. Consistent with the previous anti-nociceptive vasodilatory
treatments (Coderre et al., 2004), increased perfusion of EDL capillaries was
observed after CORM-3 injection. In addition, a decrease in leukocyte adherence
was found, although no changes in rolling leukocytes or in cell injury were observed
in CORM-3 treated animals. These results suggest that an inflammatory response,
albeit a diminished one is still occurring. Considering the length of time, elapsed
after CORM-3 treatment (i.e. 7 days) that microcirculation was directly visualised, it
is not unreasonable to see no changes in cell injury between CORM-3 treated and
CPIP animals, even with the knowledge that CORM-3 has anti-apoptotic properties.
Similar to recent work by Hamam et al (Hamam et al., 2014) on compartment
syndrome (CS), no significant changes in gait parameters were observed after
CORM-3 application. A trend toward improved function was observed after CORM-3
injection in both studies; however, dynamic gait parameters were most affected by
CORM-3 in CS, compared to a trend in static gait parameters in this study. The
complex nature of gait movements, in terms of central processing, may have
negated some of the positive effects CORM-3 had on the microvasculature, perhaps
resulting in a lack of gait improvement.
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4.2 STUDY LIMITATIONS
4.2.1

Pain Measurements
As the CPIP model in rats is a representation of the painful human condition,

CRPS-I, we are presented with an inherent limitation in regards to pain and its
measurement. Non-verbal representations of pain and hypersensitivity, using paw
withdrawal from both noxious and non-noxious stimuli, are measured in the CPIP
model. One limitation of pain and sensitivity tests is the animal handling required.
Often, pain tests require that animals be restrained for measurements. In Chapters 2
and 3, animals were taken from their resting cages and placed in small chambers for
allodynia testing with von Frey filaments. Studies have found that simple handling of
rats can cause recruitment of endogenous opioids that can result in delayed
responses to stimuli, including the stimuli used in our experiments, i.e. von Frey
filaments (Jorum, 1988; Jorum & Shyu, 1988). In an effort to remove this potential
limitation, we allowed rats to acclimatize to the new environment for a period of at
least 10-15 minutes. Even with these additional efforts, some rats tried to escape the
testing chamber after the 10-15 minute acclimatization period. Escape behaviour
may suggest that these rats had altered responses to stimuli, perhaps as a result of
endogenous opiod release.

4.2.2 Animal Model and Age of Rats
In both Chapters 2 and 3, young rats were used to produce CPIP. Animals
were ordered at a weight of 150-175 g, although a minimum weight of 200 g was
ensured before inducing the model through I-R injury. What was noticed in both
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chapters was a resiliency of the rats, as it pertains to their recovery from injury. In
some rats, no allodynia symptoms developed; these animals were subsequently
excluded from further testing. Considering that CRPS is more common in adult
patients, it may be prudent to use older rats in future experiments, in order to
account for their resilient nature with respect to recovery from any injury and/or the
development of allodynia symptoms similar to CRPS.
Other authors have cited a weight gain of 40% as being significant in the
measurement of several gait parameters (Gabriel et al., 2009). Although no
significant weight changes were observed in our experiments, the use of older rats
may help negate any chance of weight gain affecting gait parameters.
Coderre and colleagues, in the original publication of the CPIP model, used
pentobarbital injection to anesthetize rats before surgery. In our experiments, we
used inhalational isoflurane. Although isoflurane has been found to have
hypotensive and respiratory depression effects, it is an ideal anesthetic to use for
extended surgical procedures like ours. Also, if temperature is properly maintained
at normal body temperature, these side effects may be avoided. We ensured rats
were always approximately 37 degrees Celsius through the use of a heating lamp.

4.2.3 Automated Gait Analysis
To assess functional changes after induction of CPIP to model CRPS-I, we used
an automated gait analysis system. The CatWalkTM uses the refraction of light from
an animal’s paw on the glass walkway to capture images. Light is internally reflected
within the glass and only released once a paw (or any other object) touches the
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walkway. As a result, error is created if moisture or debris is present on the walkway.
Rats often urinate small amount at the ends of the walkway and drag that moisture
towards the centre of the walkway. Efforts were taken to ensure the walkway was
dry and free from debris at all times, but it was impossible to have all of the recorded
runs free of any moisture.
Several times throughout the experimental time-course rats would drag their
underside on the glass walkway. The excess contact is normally recorded by the
system as noise on the CatWalkTM software, creating a difficult situation for the
software to classify paw prints automatically. As a result, many paw prints had to be
be manually classified, inherently introducing a source of error.
Noldus, the CatWalkTM system manufacturer, has just released an improved
and more advanced analyzing software. Currently, our lab does not have this most
recent edition, which might prove to be useful in measuring functional changes in our
model, as well as in several other models of injury.

4.3 FUTURE DIRECTIONS
Considering the short half-life of CORM-3 in physiological solution, injecting
CORM-3 multiple times after initiation of the CPIP model may yield different results.
It may be interesting to see the effects this would have on how quickly paw
withdrawal thresholds are returned to baseline, or if they would be restored at all.
Building on the above direction, and in order to better observe the effects of
CORM-3, it would be beneficial to perform IVVM on some animals directly after
injury, as well as at 1, 2, and 3 days post-injection. This approach may provide a
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better insight into the effect of CORM-3 on the microvasculature, as it may be
possible to correlate the gradual restoration of paw withdrawal thresholds with the
changes directly observed within the microvasculature. It may also allow us to
examine the effects of tourniquet placement and time on microvascular changes of
the distal portion of the limb.
In examining how gait changes are caused by pain-related problems in the
CPIP model, including a known analgesic pharmacological agent may be useful.
This approach may help to ascertain the exact link between gait changes and pain
while monitoring the normalization of gait, similar to the work of Angeby-Moller and
colleagues in arthritis studies (Angeby-Moller et al., 2008).
Tissues from the skeletal muscle could be harvested from all animals at the
time of euthanasia; although beyond the scope of this study, these could be used to
examine the potential mechanisms of action of CORM-3 at a molecular level.
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4.4 GENERAL CONCLUSIONS
The work presented in this thesis is the first piece of scientific literature to
evaluate gait in the CPIP model of CRPS-I. It was hypothesized, based on the
literature describing other inflammatory conditions, that automated gait analysis may
be an objective and rapid tool for the assessment of gait changes secondary to
allodynia. The results presented here suggest that automated gait analysis in the
CPIP model is indeed a beneficial tool. We found several gait parameters correlating
with von Frey measurements of allodynia assessment. As CRPS-I patients often
lose range of motion and general function, as well as develop dystrophy/atrophy of
the affected limb, using the methodology described in this work we may be able to
better assess efficacy of potential therapeutics.
In the literature, anti-sympathetic and vasodilatory drugs have often appeared
to reduce mechanical allodynia in CPIP model of CRPS-I. Through the use of the
known vasodilatory, anti-inflammatory and anti-oxidant properties of CORM-3, this
work has shown that CO therapy is capable of reducing mechanical allodynia
symptoms in the CPIP, as indicated by an increase in paw withdrawal thresholds.
The actual effect of CORM-3 is still unclear; however, with further analysis,
mechanisms of CORM-3 action may be delineated and assist with improving our
understanding of the complex pain mechanisms involved in CRPS-I.
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APPENDIX A – DEFINITIONS OF GAIT ANALYSIS PARAMETERS
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11.01.13
*This is the original approval for this protocol*
*A full protocol submission will be required in 2017*
Dear Dr. Lawendy:
Your animal use protocol form entitled:
Direct and Remote Organ Injury Following Hind Limb Compartment Syndrome
Funding agency Orthopaedic Trauma Association – Direct and Remote Organ Injury Following Hind Limb
Compartment Syndrome – Grant #R4889A04 has been approved by the University Council on Animal Care.
This approval is valid from 11.01.13 to 11.30.17 with yearly renewal required.
The protocol number for this project is 2009-083.
1. This number must be indicated when ordering animals for this project.
2. Animals for other projects may not be ordered under this number.
3. If no number appears please contact this office when grant approval is received.
If the application for funding is not successful and you wish to proceed with the project, request that an
internal scientific peer review be performed by the Animal Use Subcommittee office.
4. Purchases of animals other than through this system must be cleared through the ACVS office. Health
certificates will be required.
ANIMALS APPROVED FOR 4 YEARS
Species
Strain
Rat
Pig

Other Detail

Wistar
Yorkshire-Landrace

150-350 g
50-60 kg

Pain
Level
C
B

Animal # Total
for 4 years
680
30

REQUIREMENTS/COMMENTS
Please ensure that individual(s) performing procedures on live animals, as described in this protocol, are familiar
with the contents of this document.
The holder of this Animal Use Protocol is responsible to ensure that all associated safety components (biosafety,
radiation safety, general laboratory safety) comply with institutional safety standards and have received all
necessary approvals. Please consult directly with your institutional safety officers.

c.c. R Bihari, T Carter, K Bothwell, P Coakwell
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